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THE IMMUNE SYSTEM 
The immune represents a highly versatile defense system that evolved to protect 
vertebrates from invading pathogens and cancer. Cells and molecules of the immune 
system are able to specifically recognize and eliminate an apparently unlimited variety 
of foreign invaders. They act together in a dynamic network and its dysregulation may 
give rise to a series of diseases (1). 
In mammals, the immune system includes innate and adaptive components. The innate 
immune system consists of soluble effector molecules and cellular components like 
myeloid cells, while the adaptive immune system is constituted by antibody producing 
B cells as well as CD4+ helper and CD8+ killer T cells. Both systems act in close 
cooperation to protect the host against pathogens (1, 2).  
Generally, the innate immune system is considered to act nonspecifically. It provides 
the first line of defense against infection. Elements of the innate immune system are 
present before the onset of infections and they are not specific to particular pathogen 
but rather recognize classes of molecules peculiar to frequently encountered pathogens 
(1-3). In contrast, the adaptive immune system is thought of as being very specific. 
This system is capable of recognizing and selectively eliminating specific foreign 
microorganisms and molecules. Moreover the adaptive immune system reacts faster 
and stronger upon re-encounter of the same pathogen i.e. it exhibits immunological 
memory (1-3). 
The adaptive immune system is coming into play when the innate immune system is 
overwhelmed by an infection, although many infections are solely cleared by innate 
immune system. A few of the pathogens can overcome innate immune mechanisms 
and adaptive immune system is essential for defense against such invaders. Therefore, 
both innate and adaptive components have to be fully synchronized. The adaptive 
immune system requires instruction from the innate immune system indicating the 
origin and nature of the antigen they recognize. For instance, T cells are unable to 
recognize antigen directly. They require antigen to be processed and presented by 
so-called antigen presenting cells. This is so-called innate control of adaptive immune 
responses and will be described extensively below (1-3). 
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1. INNATE IMMUNE SYSTEM 
The innate immune system consists of soluble molecules as well as of cellular 
components. Soluble factors can be constitutively present in circulation; some of them 
can also be induced upon infection. Cells of the innate immune system are mainly 
phagocytic, such as macrophages and neutrophils. Very important compounds of the 
innate immune system are also anatomical barriers such as skin (1-6). 
 
1.1 SOLUBLE MOLECULES 
 
A few soluble components will be described here that are essential for the innate and 
activation of the adaptive immune response. They display local as well as long range 
activities. 
 
1.1.1 The Complement System 
 
The complement system consists of more than 35 proteins. It is found constitutively in 
circulation. The main biological functions of complement are defense against 
infections and clearance of debris such as apoptotic and necrotic cells (1, 7, 8). 
Complement is activated by three different pathways: classical, lectin and alternative 
(Fig. 1.1). They share the common step of activating the central component C3, but 
they differ according to the nature of activation. The classical pathway is activated 
after formation of antibody/antigen complexes, the lectin pathway is activated after the 
recognition and binding of pathogen-associated molecular patterns (PAMPs) by lectin 
proteins, the alternative pathway is continuously „on” due to spontaneous activation of 
C3 (1, 7, 8). Activation of complement results in a cascade of enzymatic reactions that 
finally leads to a so-called membrane attack complex, which than forms pores in the 
membrane of the susceptible target (1, 7, 8). Many of the complement components are 
activated by proteolytic cleavage. The resulting peptides especially from C3 and C5 
act as an important chemoattractants called anaphylatoxins that attract cells of the 
innate immune system. The complement system is an important part of innate 
immunity but also participates in antibody response of the adaptive immune system (8, 
9). 
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Figure 1.1 Three pathways of the complement system (10) 
 
1.1.2 Type I Interferons 
 
Type I Interferons (IFNs) were discovered in 1957 by Isaacs and Lindenmann (11) and 
constitute one of the most important classes of cytokines. They are amongst the first to 
be induced during infection. Type I IFNs belong to the class II family of α-helical 
cytokines and constitute a multi-member cytokine family (13 subtypes of IFN-α, one 
IFN-β, -ε, -κ, and several -ω, -σ and –τ). IFN-σ and IFN-τ are absent in humans, IFN-τ 
was found only in ruminants. IFN-ω is closely related to IFN-α. IFN-ε is expressed in 
the placenta, therefore may play a role in reproduction, IFN-κ is expressed by 
keranocites.  
While for many of the isotypes of IFNs the function is not yet clear, for immunologists 
IFNs-α and IFN-β are the main isotypes of interest and will be taken from now on 
synonymously for type I IFNs (1, 12-15). The grouping of IFN-α and IFN-β together 
as a type I IFNs is due to the fact that they display similar amino acid sequences and 
structures and namely due to that they share the same receptor – type I IFN receptor 
(IFNAR). IFNAR is a ubiquitously expressed heterodimeric receptor composed of 
IFNAR1 and IFNAR2 chains. IFNAR2 serves as the ligand binding chain, yet both 
chains are required for signal transduction (1, 12-15).  
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IFN-β is a master type I IFNs. For instance, it is induced as first IFN upon stimulation 
of toll-like receptor 3 (TLR3) or toll-like receptor (TLR4), and acts in an autocrine and 
paracrine fashion to induce other type I IFNs isotypes (12, 15, 16). In details, binding 
to the IFNAR receptor results in cross-activation of two receptor associated tyrosine 
kinases – Jak1 and Tyk2, followed by activation of two members of the family of 
signal transducers and activators of transcription (STATs) – STAT1 and STAT2. 
Further heterodimers of STAT1/STAT2 associate with the IFN regulatory factor 9 
(IRF-9) to form the complex IFN-stimulated gene factor 3 (ISGF3). The ISGF3 can 
initiate transcription by binding to the upstream regulatory consensus sequences of 
IFN-α/β inducible genes (IFN-stimulated response elements, ISRE) (10, 15). Other 
IRF family members, IRF3 and IRF7 are required to initiate and amplify the 
expression  of type I IFNs (16).  
Beyond the well established role of type I IFNs in protection against viral and bacterial 
infections, they are also spontaneously produced under steady state conditions (16, 
17). Low, constitutive levels of type I IFNs are believed to prime the immune system 
and thus are prerequisite for enhancement of IFN-α/β production subsequent to 
infections. They serve as a so-called „weak signal for strong responses” (16-18). The 
mechanism of spontaneous production remains still unknown. Possibly, IRF-3 which 
is constitutively expressed induces very low levels of IFN-α/β, resulting in a weak 
signal through IFNAR receptor that would lead to ISGF3 dependent IRF-7 expression. 
Due to this fact upon viral infection both IRF-3 and IRF-7 are already present and 
ready to rapidly amplify the production of type I IFNs (Fig. 1.2) (16).  
Type I IFNs are highly pleiotropic cytokines. They engage a well established position 
as part of the innate immune system. In addition they have been shown as potent 
regulators of adaptive immunity more recently. They exert broad regulatory effects 
and various cell types are strongly affected by these cytokines (13, 19-21). 
For instance type I IFNs produced primarily by plasmacytoid dendritic cells (pDCs) 
during viral infection (22) stimulate maturation and activation of conventional 
dendritic cells (cDCs) and enhance antigen presentation (23-25). They exert both 
direct and indirect effects on T cells and play a key role in the fine-tuning of their 
activity by delivering both stimulatory and inhibitory signals (26). Moreover, type I 
IFNs are powerful polyclonal B-cell activators that induce a strong primary humoral 
immune response (14).  
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Figure 1.2 Week IFN-α/β signal is necessary for its amplification during antiviral        
responses (16) 
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1.2 CELLULAR COMPONENTS OF THE INNATE IMMUNE SYSTEM 
 
Almost every cell in the body is able to exert a defense reaction against pathogens and 
could be considered as a part of the immune system. Especially epithelial tissues like 
the epidermis of the skin and the mucosal tissues serve as a barrier between the body 
and environment. They should be considered as a first line of defense, protecting the 
internal tissues from environmental stresses, chemical damage and bacterial infection. 
Epithelia of the skin and oral mucosa are examples of the toughest and most protective 
epithelia (1, 27). Although, mucosal epithelia represent the major site of entry of 
pathogens, they are also responsible for a symbiotic relationship with bacterial 
microflora in the gut. Beside such cells the innate immune system includes cells that 
are specialized for certain functions in the immune reactions. 
 
1.2.1 Cells of the innate immune system 
 
Once pathogens overcome the epithelial barrier and replicate in the tissues of the host, 
they are usually rapidly recognized by migratory phagocytic and non-phagocytic cells 
of the innate immune system. To this group of cells belong blood monocytes, 
macrophages, dendritic cells, neutrophilic, eosinophilic and basophilic granulocytes as 
well as mast cells. Natural killer (NK) cells are also considered as a part of the innate 
immune system. They do not exhibit pahgocytic properties.  
Phagocytic cells of the innate immune system recognize pathogens by means of cell 
surface receptors and engulf them by a process called phagocytosis. In most cases this 
is followed by death of the pathogen. Since a major part of this thesis is concerned 
with dendritic cells they will be described more extensively below.  
 
1.2.2 Dendritic cells 
 
Dendritic cells (DCs) were identified in 1973 by Ralph M. Steinman (28). They were 
described as a family of cells that regulate the immune response. Dendritic cells 
acquired their name because they possess long membrane extensions that resemble the 
dendrites of nerve cells. Together with B cells and macrophages they are considered as 
professional antigen presenting cells (APCs) for T cells, although DCs are the most 
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efficient APCs. At the moment they appear to be an extremely heterogenous family of 
cells, yet all of them constitutively express MHC class II molecules (MHC II, see 
description below) (1, 29). At steady state DCs are phenotypically and functionally 
immature. After exposure to microbial products or inflammatory stimuli, DCs undergo 
an activation program, generally referred to as “maturation”. This process induces 
major phenotypic and functional modifications, affecting especially antigen capture, 
processing and intracellular MHC II trafficking. Mature DCs down-regulate their 
ability to take up newly encountered antigens. They also down-regulate their 
intracellular levels of MHC II while surface levels of MHC II and co-stimulatory 
molecules are dramatically up-regulated (Fig. 1.3) (29-31). 
 
 
 
Figure 1.3 Maturation and control of MHC II antigen presentation in dendritic 
cells (32) 
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1.2.2.1 Diversity of DC subsets 
 
Generally the dendritic cell family consists of conventional dendritic cells (cDCs) and 
plasmacytoid dendritic cells (pDCs). Further cDCs can be subdivided into non-
lymphoid tissue migratory and lymphoid tissue resident DCs. The major function of 
conventional DCs is maintenance of self-tolerance in steady state and induction of 
specific immune responses against invading pathogens. In contrast plasmacytoid DCs 
are also called “interferon-producing cells” and their main function is to secrete high 
amounts of type I IFNs in response to viral infections (1, 29).  
 
DCs in non-lymphoid tissues. Here, one has to mention DCs that are present in sterile 
tissues like pancreas and heart, DCs present in filtering sites such as liver and kidney, 
and finally DCs present at environmental interfaces like lungs, gut and skin. Among 
all these diverse DCs epidermal DCs also called Langerhans Cells (LCs) are the most 
studied and the best characterized population.  
Langerhans Cells were first detected in the skin by Paul Langerhans already in 1868 
(33).  At that time their role was not appreciated and they were rather considered to 
belong to the nervous system due to their morphology. LCs constitutively express high 
levels of MHC II molecules and also the lectin langerin (CD207), forming the 
intracytoplasmic Birbeck granules. However, recently it was shown that expression of 
langerin is not only specific for LCs (34, 35). In mice, it is also expressed at low levels 
on some migratory DCs in lymphoid organs and on some DCs populations present in 
lungs and dermis.  
Tissue DCs sample antigens from the environment and migrate constantly through 
afferent lymphatics to the T cell areas of draining lymph nodes (LN). Here they 
present acquired antigen to T and B cells (1, 29, 30, 36).  
 
DCs in lymphoid tissues. Five major DC subsets have been identified in lymphoid 
tissues of uninfected laboratory mice. Generally they all express high levels of CD11c 
molecule (the α chain of integrin CR4) and MHC II molecules. Four other markers can 
be used additionally to further define DCs subpopulations: CD4 (a member of the 
immunoglobulin superfamily and co-receptor for MHC II mediated activation of T 
cells), CD8α (a membrane bound dimer of two α chains, also a member of the 
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immunoglobulin superfamily and co-receptor for MHC I mediated activation of T 
cells), CD11b (the α chain of MAC-1 integrin) and CD205 (DEC-205, a C-type 
lectin).  
In spleen all DCs express CD11c and MHC II. They can be further divided on 2 major 
subpopulations: CD4+CD8α-CD11b+ (shortly called also CD8α- DCs). Recently it was 
shown that this population also expresses the antigen recognized by the 33D1 
monoclonal antibody – CD8α-33D1+ (37). The second population is CD4-
CD8α+CD11b- (shortly called also CD8α+ DCs). This population additionally 
expresses CD205 molecule. CD4-CD8α-CD11b+ DCs have been also described and 
called shortly double negative DCs. The particular subpopulations also differ by their 
localization in the spleen. The majority of CD8α- DCs are found in the marginal zone, 
whereas CD8α+ DCs are present in T cell areas (1, 29, 30, 36). 
DCs found in the LNs are more heterogenous as they include additional migratory 
subpopulation. Therefore, in the LN are present: CD8α+ DCs, CD8α- DCs, double 
negative DCs and migratory DCs, which enter via afferent lymphatics. About one third 
of DCs from LN are migratory DCs.  Generally, they were shown to exhibit following 
phenotype: CD4-CD8αlow(lo)CD11b+ and CD205high(hi). Such migratory DCs may also 
express additional markers, which vary according to the site drained by the LN.  For 
example migratory dermal DCs will express langerin (CD207) and they can be found 
in subcutaneous LN (1, 29, 30, 36). 
DCs present in mucosa-associated lymphoid tissues like Peyer patches and isolated 
lymphoid follicles in the small intestine or in isolated follicles and appendix in the 
large intestine phenotypically resemble splenic DCs. 
Thymic DCs localize in the medulla and the majority of them express CD8α. A minor 
subpopulation is CD8α- and displays the signal regulatory protein-α (sirp-α). Thymic 
DCs play a major role in negative selection of T cells, i.e. in the induction of central 
tolerance (29, 30). 
 
Plasmacytoid DCs (pDCs). Mouse pDCs has been indentified recently (38-41). These 
cells have a unique surface phenotype: CD45RAhiB220+CD11cloCD11b-MHC IIlo. 
Additionally, they express the PDCA1 and siglec-H molecules, recently identified as a 
specific surface markers for mouse pDCs (42). Mouse pDCs are known to produce 
large amounts of type I IFNs in response to viral stimulation. Therefore they are also 
called “interferon producing cells”  (IPCs) (29).  
INTRODUCTION 
21 
 
 
 Figure 1.4 Mouse DC populations (29) 
 
1.2.2.2  Origin  of DCs 
 
DCs originate from hematopoietic stem cells (HSCs) present in the bone marrow. 
Here, the self-renewing HSCs give rise to two major developmental pathways of DCs: 
lymphoid and myeloid. Initially it has been suggested, that DCs are exclusively of 
myeloid origin, since they share many features with monocytes and macrophages (43). 
Now it is known that both the common myeloid progenitor (CMP) as well as the 
common lymphoid progenitor (CLP) from bone marrow can give a rise to DCs. (44-
46). Moreover, by several experimental approaches it has been shown that both CMP 
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and CLP can differentiate into all types of DCs indicating the plasticity of the 
hematopoetic development (43, 47). Almost all early DCs precursors have been found 
to express FMS-related tyrosine kinase 3 (Flt-3) (29). An additional intermediate 
precursor was described that lacks lineage specific markers- lin-, and expresses the 
markers CX3CR1
 and CD117. This precursor is common to both macrophages and 
DCs, it was shown to be able to differentiate into cDCs but not into pDCs, which 
indicates the branch for pDCs development (43, 48, 49). Finally the late DCs 
precursors express already CD11c, the marker that is common to all DCs. They still 
lack surface MHC II expression. In the bone marrow very few developed cDC are 
found since the final differentiation normally takes place in peripheral organs (43, 49). 
 
1.2.2.3  Differential antigen presentation capacity of DC subsets 
 
Several studies have revealed that particular subpopulations of DCs display 
specialized antigen presenting abilities (53, 54). Especially only CD8α+ DCs possess 
the machinery to efficiently cross-present antigens, i.e. to present exogenous antigens 
via MHC I) in vivo (37, 50). Similarly, ex vivo isolated, tissue resident CD8α+ DCs 
were shown to be the most efficient population in cross-presentation experiments. 
Nevertheless, CD8α+ DCs can also efficiently present antigen via MHC II molecule 
and activate CD4+ T cells. The role of CD8α- DCs is less well understood. Tissue 
resident CD8α- DCs can generally cross-present antigens, but are much less efficient 
in comparison to CD8α+ DCs. Their role in antigen presentation to CD4+ T cells via 
MHC II molecules is much more prominent (31, 51). Double negative DCs were 
shown to be functionally very similar to CD8α- DCs (50). Non-lymphoid tissue 
migratory DCs were found to play a crucial role in the presentation of antigens present 
in the peripheral tissues (31, 51). And finally, pDCs are generally considered as poor 
presenters of exogenous antigens but they can efficiently present endogenous antigens 
for instance during viral infections (31, 52, 53). 
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1.3 RECOGNITION OF NON-SELF MOLECULES BY THE INNATE IMMUNE 
SYSTEM 
Innate immune antigen recognition (also called pattern recognition) relies on a limited 
number of germline-encoded receptors (2, 5, 6). This recognition is based on the 
detection of molecular structures that are unique to microorganisms. Each host 
receptor, called also pathogen recognition receptor (PRR) can bind to a large number 
of molecules that have a common structural motif or pattern, so-called pathogen-
associated molecular patterns (PAMPs). Bacterial PAMPs are often components of the 
cell wall, such as lipopolysaccharide, peptidoglycan, lipoteichioc acid and cell wall 
lipoproteins. Thus, the detection of these structures by the innate immune system 
signals the presence of microorganism. The recognition of viruses also follows this 
principle. Here, however targets for immune recognitions usually are viral nucleic 
acids or replication intermediates (2, 5, 6, 54). 
The family of Toll-like receptors (TLRs) is the major and the most extensively studied 
class of PRRs. TLRs can be divided into subfamilies recognizing related PAMPs: 
TLR2 as heterodimer with TLR1 or TLR6, and TLR4 recognize glycolipids, TLR3, 
TLR7, TLR8 and TLR9 recognize nucleic acids. The most important cell types 
expressing TLRs are APCs including DCs,  macrophages and B cells (1, 2, 5, 6, 54). 
C-type lectin receptors (CLR) are another group of proteins involved in innate 
recognition. These receptors recognize carbohydrate structures on cell wall 
components of microorganisms. One of their major functions is to internalize antigens 
for lysosomal degradation. To this family of receptors belong molecules like: mannose 
receptor (MR, CD206), DEC-205 (CD205), dectin-1, langerin (CD207), DC-SIGN 
(CD209), SIGN-R1 (CD209b) (55, 56). 
Another class of PRRs is found intracytosolic and includes nucleotide-binding 
oligomerization domain proteins (NOD) and RIG-I-like receptors (RLR). Such 
receptors are responsible for the recognition of viral infections but are also activated 
by certain bacteria or even small molecules (1, 2, 5, 6, 54).  
Triggering of such receptors usually results in activation of signaling pathways that 
include NFκB and MAP kinases. This results in the induction of defense mechanisms 
like induction of type I IFNs or proinflammatory cytokines as well as a general 
activation of the cells of the immune system (57). 
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Figure 1.5 Innate recognition receptors – overview (6) 
 
2. ADAPTIVE IMMUNE SYSTEM 
 
In most cases the innate immune reaction is sufficient to control and clear the 
pathogen. Yet, some of the invaders developed sophisticated evasion mechanisms, 
such that a more specific response is required to defeat them. This is achieved by 
effector mechanisms of the adaptive immune system. The adaptive immune system is 
capable of recognizing and selectively eliminating specific foreign antigens. It is not 
independent of the innate immune system. Phagocytic cells and soluble molecules 
belonging to the innate immune system are particularly involved in activating and 
directing the specific immune response. This highly regulated interplay of innate and 
adaptive immune systems ensures, the most efficient way of eliminating foreign 
invaders (1). 
 
2.1  CELLS OF THE ADAPTIVE IMMUNE SYSTEM 
 
Lymphocytes are the cells constituting the adaptive immune system. Two major types 
of lymphocytes exist – T lymphocytes (T cells) and B lymphocytes (B cells). 
Lymphocytes are one of the many types of white blood cells produced in the bone 
marrow in the process of hematopoesis (1). T cells received their name because they 
further develop in thymus from precursors generated in the bone marrow, whereas B 
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cells are named according to their organ of origin in birds, the Bursa of Fabricii. In 
mammals they develop in bone marrow. 
 
2.1.1 B cells 
The most important task of B cells is to produce antibodies, thus they are responsible 
for humoral immunity. Primarily they are produced in fetal liver before birth and in 
bone marrow afterwards. B cells express antibodies as antigen-binding receptor on 
their membrane, the so-called B cell receptor (BCR). The BCR consists of two 
identical heavy and two identical light chains. While the C-terminal region of both 
chains is constant, the N-terminal region displays a high variability of sequences. Such 
variable regions are encoded in germline by several gene segments (V, D, J for heavy 
chain and V, J for light chain). During B cell development, the variable region (V) of 
both chains is assembled by rearrangement of the particular gene segments at the DNA 
level thus providing the basis for the extensive diversity of the BCR (1). 
Binding of antigen to BCR together with appropriate help of T cells, causes B cells to 
rapidly divide and differentiate into memory B cells or plasma cells. Plasma cells 
represent effector B cells, which can produce vast amounts of antibodies in a secreted 
form, while memory B cells are the basis for the long lasting immunity against 
pathogens that an individual had encountered already once before. Besides their task to 
produce antibodies, B cells also are able to present antigen to T cells and produce 
immunoregulatory cytokines (58, 59). 
B cells can be subdivided into several subpopulations. B2 cells are the major 
population in the circulation and spleen. They are responsible for highly specific 
antibody responses and the formation of the memory. B1 cells dominate the body 
cavities and are responsible for the production of natural antibodies (1, 60, 61). In the 
spleen there is also special B cell population, so-called marginal zone (MZ) B cells, 
which is described in more details in the next section. 
 
2.1.1.1 Marginal Zone B cells 
 
MZ B cells are uniquely located within the MZ of the spleen (Fig. 1.6) where the 
splenic arterioles open into a sinus and allow contact with blood. Generally MZ B 
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cells are responsible for early antibody responses to blood-borne pathogens that have 
entered the spleen. This response is fast and efficient, because MZ B cells have a 
reduced threshold for activation, proliferation and differentiation into antibody-
secreting cells compared to other B cells (60-63). Although MZ B cells are defined 
primarily on the basis of their special anatomical location, the expression of a number 
of surface markers can be used to characterize these cells in more details.  
MZ B cells express high levels of IgM, very low levels of IgD and CD23 (low affinity 
receptor for IgE). They also express high levels of CD21 (complement receptor type 
II), CD1d (MHC class Ib protein responsible for presentation of lipid antigens), CD9 
(a scavenger receptor family protein) and CD25 (the α chain of IL-2 receptor). In 
addition, MZ B cells express high levels of co-stimulatory molecules, therefore they 
are often described as having an “activated” phenotype (62, 63).  
MZ B cells were shown to play an important role in activation of other immune cells 
and regulation of their functions. This is mainly due to their special anatomical 
location, which allows them to have close contact with T cells, dendritic cells and 
NKT cells (64).  
Importantly, MZ B cells have been recently shown to be not strictly confined to the 
MZ as believed before (65). They continuously shuttle between MZ and follicles in the 
white pulp of the spleen. This feature of MZ B cells facilitates transport of the blood-
borne antigens to the DCs present in the follicles. Subsequently such DCs assist in the 
maturation of B cells by presentation of an intact antigen. In addition continuous 
shuttling of MZ B cells between MZ and white pulp follicles ensures efficient 
transport of T cell independent, blood derived antigens to follicular DCs and B cells 
(66). 
 
2.1.2 T cells 
 
The second major lymphocyte population, the T cells are also derived from bone 
marrow precursors. They migrate to the thymus where they undergo final 
differentiation. During maturation T cells express a unique-antigen binding 
heterodimeric molecule, the so-called T cell receptor (TCR) on their membrane, 
consisting of chains of equal size. Similar to the BCR, the two chains consist of a 
variable and a constant region and the variable parts are formed during ontogeny in the 
thymus by DNA rearrangement of particular gene segments. Once matured, T cells  
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Figure 1.6 Particular anatomical location of the MZ B cells (172) 
 
emigrate from the thymus and remain in circulation or migrate into the secondary 
lymphoid organs like spleen or LN.  
T cells can be divided into two major subclasses, according to cell surface receptor 
expression. The majority of T cells express TCRs consisting of α and β chains, and the 
second group express TCRs made of γ and δ chains. The function of the latter T cell 
group is still enigmatic. 
Among T cells which express α/β TCR there are two major subclasses, CD4+ and 
CD8+ T cells. They are different in the way they recognize antigen  and by their 
effector functions (1, 67, 68). CD4+ T cells recognize antigen presented via MHC II 
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and CD8+ T cells recognize antigen presented via MHC I. CD4+ T cells function as a 
so-called T helper cells (TH), i.e. by cell cell contact or secretion of cytokines they aid 
other immune cells like macrophages, DCs or B cells to differentiate. As a 
consequence of priming TH cells can develop into TH1 cells (which mainly produce 
IFN-γ and lymphotoxin), TH2 (which produce IL-4, IL-13, IL-5, IL-6 and IL-10), 
TH17 (which produce IL-17) (1, 67-69). TH1 cells are inducers of cellular immune 
responses, for example they enhance activity of macrophages. TH2 cells help B cells to 
develop into antibody producing plasma cells and regulate the isotype switch that 
allows B cells to change the C-terminal constant region. TH17 cells can efficiently 
recruit granulocytes into the sites of inflammation (69, 70).  
Another recently discovered CD4+ T cell population is so-called regulatory T cells 
(Treg) population. They express the forkhead box P3 (Foxp3) transcription factor and 
CD25 (α chain of IL-2 receptor). Treg play a crucial role in maintenance of tolerance 
and in regulation of immune responses in general (71). 
CD8+ T cells are also called cytotoxic or killer T cells. They are particularly involved 
in fighting against intracellular pathogens. After activation they are capable to 
efficiently lyse target cells. To eliminate infected cells they are using two principal 
mechanisms, one is perforin dependent, one Fas/FasL dependent. CD8+ T cells can 
also interfere with infections by producing cytokines like IFN-γ or TNF-α (1, 68).  
 
2.1.3 NKT cells 
 
NKT cells were independently identified as a separate lineage of T cells. They are 
generally defined as T cells expressing NK lineage receptors, including NK1.1. At the 
same time they express a semi-invariant CD1d (see description below) restricted α/β 
TCR (72-75). The TCR of such NKT cells in most cases consist of Vα14-Jα18/Vβ8, 
Vβ7, Vβ2 chains in mice. Therefore, these cells are often called invariant Vα14 NKT 
cells. Ligands for activation of NKT cells via CD1d molecules include: 
α-galactosylceramide (αGalCer) from a marine sponge Agelas mauritianus, microbial 
ligands derived from Gram-negative, LPS negative members of the class of α-
proteobacteria Sphingomonas sp., and self ligands like isoglobotrihexosylceramide 
(iGb3).  
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Once NKT cells recognize lipid antigen presented by CD1d molecules they rapidly 
start within hour to massively produce cytokines like IL-4 or IFN-γ. This is quite in 
contrast to normal TH cells, which are permanently driven into either IFN-γ producing 
TH1 cells or IL-4 producing TH2 cells. The contrary outcome of rapid cytokine 
production (TH1 versus TH2 response) is only partially understood.  
Additional functions on NKT cells are numerous and they include roles in clearing 
infections, autoimmune disorders, allergic responses and tumor immunity (75). When 
clearing an infection NKT cells may act directly by lysing infected cells or through 
production of cytokines that enhance the innate response and indirectly drive adaptive 
immune responses. In tumor immunity NKT cells may kill CD1d-expressing tumor 
cells directly or indirectly through the activation of NK cells. Moreover NKT cells can 
provide direct help to B cells for antibody production. A cross-talk between DCs and 
NKT cells also takes place: NKT cells rapidly secrete TH1 or TH2 cytokines which 
might activate DCs to prime CD4+ and CD8+ T cells responses, driving them into 
particular direction depending on the cytokines produced (Fig. 1.7) (72). 
NKT cells can be also activated indirectly via cytokines produced by APCs. For 
example, triggering of TLR signaling can lead to secretion of IL-12 by DCs, which in 
turn enhances the ability of NKT cells to present endogenous lipid ligands, like iGb3, 
independent of TCR triggering (72). 
 
2.2 RECOGNITION OF NON-SELF MOLECULES BY THE ADAPTIVE IMMUNE 
SYSTEM 
 
The adaptive immune system of lymphocytes faces the same problem as the innate 
immune system, namely how to distinguish between self and non-self molecules. 
However the strategy employed by adaptive immune system is completely different 
from those which evolved for the innate immune system. Adaptive immune 
recognition is mediated by two types of antigen receptors: T cell receptor (TCR) and 
B cell receptor (BCR). These receptors are highly specific, and constitute a vast 
recognition repertoire that ensures that the adaptive immune system can detect any 
possible antigen encountered throughout life (1-3). TCR and BCR diversity is 
generated through site-specific DNA recombination and each receptor of a particular 
specificity is expressed in a unique clone of lymphocytes.  
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Figure 1.7 Cellular and molecular networks of NKT cells (72) 
 
Due to the tremendous repertoire of specificities of such receptors also binding 
specificities towards self-molecules are found amongst them. To avoid self-reactivity, 
lymphocytes that react with self antigens are deleted during lymphocyte development 
(clonal deletion). This process is called induction of self-tolerance (1). 
Importantly, T cells are peculiar in their way to recognize their cognate antigen. The 
TCR can recognize antigens in a form of “denaturated, unfolded, sequential 
determinants” and only when they are bound to MHC molecules (antigen 
presentation). CD4+ T cells recognize antigens presented by MHC II and CD8+ T cells 
recognize antigens presented by MHC I. In contrast, B cells can recognize free antigen 
without prior modification. In both cases, recognition of cognate antigen initiates the 
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proliferation of specific lymphocyte clones and expands the clone to a number 
sufficient to be effective in the immune defense reactions (clonal expansion).  
In addition to direct activation of innate immune defense PRR also participate in the 
induction of adaptive immune recognition. Once a lymphocyte recognizes the antigen 
by its specific receptor, it requires instruction about the origin of the antigen. Such 
instructions are often derived from signals that are induced by PRRs on so-called 
antigen presenting cells (APCs). This is one of the basic principles of innate control of 
adaptive immunity, i.e. antigen recognized by lymphocytes associate with signals 
derived from recognition of PAMPs by PRRs (1-3, 76). 
Which cells can activate T cells via antigen presentation and how antigen is processed 
and presented is described in details below. 
 
ANTIGEN PROCESSING AND PRESENTATION 
Since the discovery that T cell mediated immunity relies on “denaturated, unfolded, 
sequential determinants” of proteins immunologists have been fascinated with antigen 
processing and presentation. Many years of work have elucidated the pathways that 
generate peptide-MHC complexes. Now most of the components and mechanisms of 
the two major pathways of antigen processing and presentation are known (1, 77). 
 
1. ANTIGEN PRESENTATION VIA MHC I 
 
The MHC I presentation pathway is active in virtually all nucleated cells. It provides a 
mechanism for displaying at the cell surface a sample of peptides derived from 
proteins that are synthesized within the cell. This is true for self-proteins in steady 
state as well as for instance for viral proteins of infected cells. In consequence, the 
internal content of the cell is constantly displayed for detection by cytotoxic CD8+ 
T cells allowing them to efficiently recognize and kill infected targets.  
 
1.1  STRUCTURE OF MHC I 
 
The structure of the MHC I molecule is optimized for presentation of particular 
antigens. The three-dimensional structure of MHC I was resolved by P.J.Bjorkmann in 
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1987 (78). Classical MHC Ia molecules are trimeric structures comprising a membrane 
bound heavy chain with three extracellular domains (α1, α2, α3) that associates non-
covalently with β2-microglobulin (β2m) and a small peptide from 8-10 amino acids in 
length (Fig. 1.8). The α1 and α2 are highly polymorphic domains. The two helices and 
the 8 β-pleated sheets of α1 and α2 form a groove for peptide-binding and 
presentation. The conserved immunoglobulin-like α3 domain is found proximal to the 
membrane and is connected with the transmembrane domain followed by a short 
inatracellular cytoplasmic tail (1, 79-81). In addition to classical MHC I molecules 
there are non-classical MHC Ib molecules, like the CD1d molecule with a binding 
groove for lipid antigens, which will be described further below.  
 
 
Figure 1.8 Ribbon representation of MHC I molecule with bound peptide (1) 
 
MHC I molecules are assembled in the lumen of the endoplasmic reticulum (ER). It 
requires help of molecular chaperones such as calreticulin, ERp57 and the accessory 
molecule tapasin (1, 79-81). The α1 and α2 domains of MHC I molecules are very 
variable due to high genetic polymorphism. In fact, MHC molecules represent the 
most polymorphic genes of mammals. Three independent loci are found to encode 
different MHC Ia molecules in both human and mouse, although many mouse strains 
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carry only two of such MHC I genes. Therefore each heterozygous individual can 
express up to six different MHC I molecules. The protein encoded by each allele can 
bind different sets of peptides. The total number of distinct peptides that can bind to a 
MHC I molecule of a given allele is estimated in the billions (1, 79-81). This might be 
essential for the immune system to fight fast proliferating pathogens that otherwise 
might escape immune recognition. 
 
1.2  PROCESSING OF ANTIGENS FOR MHC I PRESENTATION 
 
Peptides presented on MHC I molecules are derived from intracellular antigens (both 
pathogen encoded and host derived). They are generated primarily by the ubiquitin-
proteasome pathway in the cytosol. Presentation via MHC I favours newly synthesized 
proteins and especially aberrant translation products (defective ribosomal products -
DRiPs) for degradation. Therefore, such proteins are captured before they transit to 
various other locations within the cell, which would be otherwise distant from the 
antigen presentation machinery. This mechanism allows also presentation of proteins 
with long half-lives and newly translated viral gene products early during infection (1, 
80, 82).  
 
1.2.1  Degradation of antigens by proteasome 
 
Recognition of proteins by the degradation machinery for MHC I presentation usually 
requires ubiquitinylation. This multienzymatic step was shown to be dependent on 
several chaperones, like Hsp90 (1, 80, 81). Such ubiquitinated proteins are then 
targeted to the proteasome for proteolysis.  
Two types of proteasomes exist: 26S proteasome, which is active under non-
inflammatory conditions and the so-called immunoproteasome, which is assembled 
after exposure of target cells to IFN-γ. The 26S proteasome is composed of a 20S core 
particle and a 19S regulatory complex. The 20S core part is responsible for substrate 
proteolysis, while 19S part is responsible for substrate recognition.  
The 26S proteasome exhibits three enzymatic activities: chymotrypsin like (cleavage 
after hydrophobic residues), trypsin like (cleavage after basic residues), and caspase 
like (cleavage after acid residues). Stimulation with IFN-γ leads to incorporation of 
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new catalytic subunits into the proteasome and the immunoproteasome is generated 
(Fig. 1.9). In general the proteasome produces peptides 2-25 amino acids in length, 
most of which are rapidly degraded by cytoplasmic peptidases (79, 80, 83).  
 
 
 
   Figure 1.9 Formation of immunoproteasome (84) 
 
1.2.2 Proteasome independent antigen processing 
 
Most of the peptides for MHC I presentation are generated in a proteasome dependent 
way. Nevertheless, the use of specific inhibitors for proteasomes revealed that 
generation of some peptides could not be blocked. This suggested that alternative 
mechanisms have to exist. One potential candidate appears to be tripeptidyl peptidase 
II (TPPII). Degradation by TPPII is however limited to few proteins only. In most 
cases TPPII acts as a downstream of the 26S proteasome. Hence, it cleaves products 
that are released from the 26S proteasome (80, 85). 
 
1.2.3 Post-proteasomal processing of antigens 
 
The proteasome destroys more peptides than it generates. Only 15% of peptides 
generated via proteasomal degradation have the correct size. The majority of them is 
too short to be presented. Presentable peptides generated by the proteasome have the 
correct C-terminus end to bind to the peptide binding groove of MHC I, most likely 
due to co-evolution of both complexes. However they might still require further 
trimming at the N-end. This can be achieved by aminopeptidases present in the cytosol 
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and the ER (80, 86, 87). To this group of enzymes belong leucine aminopeptidase and 
puromycin-sensitive aminopeptidase, which are present in the cytosol (86, 87). 
 
 
1.2.4 Final  trimming  of  peptides  and  loading  on  MHC I  molecules  in the 
endoplasmic  reticulum 
 
Peptides generated in the cytosol of the cell have to be translocated across the ER 
membrane in order to be loaded onto MHC I molecules. This transport can be 
achieved by the transporter associated with antigen processing (TAP) localized in the 
membrane of the ER and cis-Golgi (1). TAP is a heterodimer composed of two 
subunits, TAP1 and TAP2, both of which are essential and sufficient for peptide 
translocation. Peptides transported via TAP have a length between 7 to over 20 amino 
acids. Therefore some of them still require trimming before loading onto the MHC I 
molecule is complete. At least two aminopeptidases are known to be involved in this 
process: endoplasmatic reticulum associated peptidase I (ERAP I) and L-RAP. 
Trimmed peptides will then fit into the binding groove of the assembling MHC I 
molecules (1, 80, 83, 86). 
MHC I/peptide assembly requires a number of chaperones. They help in folding of the 
MHC I heavy chain, and its binding to β2m. Tapasin is the protein, which physically 
bridges the dimer of heavy chain and β2m to TAP. Tapasin also allows only high 
affinity peptides to bind. Other chaperones involved in this process are calreticulin and 
thiol oxidoreductase ERp57. ERp57 is crucial for the recruitment of MHC I molecules 
into the peptide loading complex, calreticulin appears to be important for the 
optimization of peptide loading (1, 80, 83, 86). Once peptide is loaded onto MHC I, 
the complex is transported via the constitutive secretory pathway through the Golgi 
apparatus to the cell surface. Here the MHC I/peptide complex can be recognized by 
the TCR of CD8+ T cells (Fig. 1.10, 1.11) (81, 83). 
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Figure 1.10 MHC I assembly and loading pathway (88) 
 
 
Figure 1.11 Classical pathway of MHC I antigen processing (89) 
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1.2.4 Cross-presentation pathway 
 
Cross-presentation was initially observed by Michael Bevan in 1976 (90). He showed 
that priming of cytotoxic CD8+ T cells can be initiated via presentation of exogenous 
antigens on MHC I molecules. He called it “cross-priming”, therefore presentation of 
exogenous antigens via MHC I, which results in cross-priming of CD8+ T cells is 
called cross presentation. Only DCs were shown to be able to cross-present exogenous 
antigens. The mechanism of cross-presentation allows DCs to induce protective 
immune response against pathogens which do not directly infect DCs or against 
tumors which do not originate from DCs (91, 92). Cross-presentation is generally 
biased toward cell-associated antigens and antigens released during cellular 
destruction but autoantigens and soluble antigens are also cross-presented but with 
lower efficiency (1, 91, 92). The cell-biological mechanisms underlying of cross-
presentation are not fully resolved yet, but nearly complete scenario for soluble 
antigen came out in 2008 due to the work of Sven Burgdorf and Christian Kurts (91).  
They showed that cross-presentation is spatially and mechanistically separated from 
classical presentation of endogenous antigens via MHC I. The scenario for cross-
presentation of soluble antigen appears as follows: soluble protein is taken up by DCs 
into compartments specialized for cross-presentation, i.e. early endosomal 
compartments. From there, the protein is exported into the cytosol (the mechanism is 
not fully resolved yet, probably via sec61 molecules) and degraded by the proteasome. 
Products of degradation are reimported via TAP into the same endosomal 
compartment for loading onto MHC I molecules. From these endosomes, cross-
presented antigen is transported directly to the cell membrane for presentation to CD8+ 
T cells (Fig. 1.12). Importantly, here for the first time authors showed the presence of 
specialized early endosomal compartments, which most probably are a prerequisite for 
efficient cross-presentation (91). This experimentally established mechanism still 
raises a lot of questions, which hopefully can be answered in near future. 
It is important to mention, that another group recently showed presence of antigen 
storage compartments, characterized as a lysosome-like organelle (93). This 
intracellular antigen depot facilitates prolonged cross-priming capacity of DCs, once 
immune complexes are antigen source. Nevertheless, whether this compartment could 
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cooperate during cross-presentation with early endosomal compartment showed by 
Burgdorf et.al.(91), is still very enigmatic. 
 
 
 
Figure 1.12 Cross-presentation pathway, adapted from (91) 
 
2. ANTIGEN PRESENTATION VIA MHC II 
 
The MHC II pathway, also called endocytic pathway, is restricted only to professional 
APCs which constitutively express MHC II molecules, like DCs and B cells. MHC II 
molecules bind peptides derived from antigens of exogenous origin that are 
internalized by endocytosis and are processed within the endocytic compartments. 
MHC II molecules can also present peptides derived from endogenous proteins in a 
process called autophagy. Autophagy is believed to deliver cytoplasmic proteins to 
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lysosomes (1, 83). Presentation of antigen via MHC II leads to activation of specific 
CD4+ T cells which further may regulate almost all components of adaptive immunity 
(1, 83). 
 
2.1  STRUCTURE OF MHC II 
 
The X-ray structure of MHC II was determinated in 1993 by Jerry H.Brown (94). 
MHC II molecules contain two different polypeptide chains of nearly equal size - α 
and β chains. They are non-covalently associated together. Each chain contains two 
external domains: α1 and α2 domains and β1 and β2 respectively (Fig. 1.13).  
Structurally MHC II molecules show high similarity with MHC I molecule especially 
concerning the peptide binding groove, yet the binding groove of MHC II can bind 
longer peptides, 13-18 amino acids in length (1).  
 
 
Figure 1.13 Ribbon representation of MHC II molecule with bound peptide (1) 
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Upon synthesis in the ER, the α and β chains immediately associate and assemble with 
a third protein, the invariant chain (Ii). The Ii serves both to prevent random peptides 
from binding to the groove of the MHC II molecule on their way to proper subcellular 
site, and to direct MHC II molecules to this cellular compartment. The destination site 
for empty MHC II molecules are late endosomal compartments called MHC II 
compartments (MIIC) (1, 83) (Fig. 1.14). Interestingly, recently Ii was also shown to 
regulate migration of DCs (95).  
 
2.2  PROCESSING OF ANTIGENS FOR MHC II PRESENTATION 
 
Peptides loaded onto MHC II molecules are generated after endocytosis by 
endosomal/lysosomal proteases. Enzymes involved in this process are: 
endopeptidases, exopeptidases and IFN-γ induced lysosomal thiol reductase (GILT). 
Most of these enzymes exhibit broad specificities and their action is most likely 
redundant. The activity of such enzymes is regulated by several factors including pH 
(acidic pH), concentration of endogenous inhibitors, activators and chaperones (1, 87, 
96) 
 
2.2.1 Processing of Ii and peptide loading onto MHC II molecules 
 
Once the MHC II/Ii complex is assembled in the ER and has reached the MIIC 
removal of Ii is started. Degradation of Ii is mediated by cysteine proteases like 
cathepsin S and L. This process leads to the formation of the peptide - CLIP (class II 
invariant chain-associated peptide), which still occupies the MHC II binding groove. 
CLIP has to be exchanged for an antigenic peptide to from a proper MHC II/peptide 
complex. This exchange is facilitated by the chaperon H2-M, which directly interacts 
with MHC II molecules and stabilizes its open conformation. Antigenic peptides for 
loading onto the binding groove of MHC II molecules are available due to fusion of 
endo-lysosomal processing compartments with the MIIC. This allows the exchange of 
CLIP with antigenic peptides. However, only high affinity peptides form MHC 
II/peptide complexes with a closed loaded conformation for a sufficient length of time 
for the MHC molecules to be released from H2-M and to be transported to the cell 
surface (kinetic proof reading). Such MHC II/peptide complexes can be stable for long 
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time at the cell surface and can be recognized by the TCR of CD4+ T cells (Fig. 1.15) 
(1, 83, 87, 96). 
 
 
 
Figure 1.14 Electron microscopy micrograph of ultrathin cryosection of DC. 
Immunogold labeling of CD1b (small gold) and MHC II (large gold) within MIIC 
(173).  
 
 
3. PRESENTATION OF LIPID ANTIGENS VIA CD1 
 
CD1 molecules are MHC-like proteins (MHC Ib) that bind and present lipid antigens. 
Still little is known about intracellular pathway leading to lipid presentation. The CD1 
family consists of five members (CD1a to e) with multiple potential isoforms of each 
gene. Humans carry all five genes whereas mice posses only the CD1d gene. These 
molecules present self and non-self lipid antigens to a specialized population of T 
cells, NKT cells (1, 97-100).  
 
3.1  STRUCTURE AND TRAFFICKING OF CD1d MOLECULES  
 
CD1d is a type I integral membrane protein with the α1, α2, α3 extracellular domains 
of heavy chain non-covalently associated with β2microglobulin (β2m), analogous to 
MHC I molecule. A major difference is that CD1 molecule has a more limited 
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Figure 1.15 MHC II presentation pathway (32) 
 
polymorphism in comparison to MHC I molecules. The structure of CD1d is quite 
flexible and unstable when not filled with ligand (Fig. 1.16) (1, 100).  
Newly generated CD1 α chains are glycosylated in ER and correct folding is assisted 
by interaction with several chaperones like calnexin, calreticulin and ERp57. Further 
stabilization of the complex is followed by association with β2m. However, the 
existence of β2m free forms of CD1d has been also reported. Interestingly, these forms 
were also able to activate CD1-restricted T cells (57, 60). The antigen binding groove 
of the CD1 molecule is relatively large and hydrophobic. In the ER newly synthesized 
CD1 molecules are loaded with endogenous lipids to stabilize the antigen binding 
groove. To such lipids belong: glycosylphosphatidylinositol (GPI) and 
phosphatidylinositol (PI). The loading of lipid antigens requires activity of lipid 
transfer proteins like microsomal triglyceride transfer protein (MTP) (97-99). 
Subsequently, CD1 molecules migrate through the Golgi apparatus to the cell surface. 
From here they are re-cycled by entering the so-called sorting endosomal 
compartments with help of the AP-2 adaptor protein. In the next step, CD1 molecules 
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interact with the AP-3 adaptor protein and are directed deeper towards lysosomes and 
the MHC II compartments (MIIC) (97-99).  
 
 
 
 
Figure 1.16 Ribbon representation of human CD1d with αGalCer (101) 
 
3.2  PROCESSING AND PRESENTATION OF LIPIDS 
 
Lipid antigen uptake occurs via endocytosis. Several proteins are known to mediate 
engulfment of such lipid and glycolipid antigens, like apolipoprotein E (Apo-E). Apo-
E can efficiently deliver lipid antigens to endosomal compartments, where they are 
processed by different endosomal/lysosomal glycosidases. Next lysosomal lipid 
transfer proteins, such as saposins might transfer processed lipid antigens for loading 
onto CD1 molecules. Loading of lipid antigens onto CD1d molecules is enhanced at 
acidic pH. The CD1/lipid antigen complexes are delivered to the cell surface for 
presentation to CD1-restricted T cells (Fig. 1.17) (97-99). 
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Figure 1.17 CD1d presentation pathway (1) 
 
4. HEAT  SHOCK  PROTEINS  IN  ANTIGEN  PRESENTATION 
 
Interestingly, heat shock proteins (Hsp) have been shown to be involved in antigen 
processing and presentation. For instance, as mentioned above, Hsp90 is required for 
the ubiquitination of proteins destined for processing. But other activities were also 
observed. 
Heat shock proteins were discovered in 1974 (102). They are categorized into several 
families and named on the basis of their approximate molecular weight (103). These 
proteins are localized in various cellular compartments and may function as molecular 
chaperones. They can take part in the assembly, stabilization, folding and translocation 
of proteins and peptides (103, 104). 
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Hsp70 is the most conserved protein in evolution. Chaperoning function for Hsp70 
proteins is characteristic and essential for Hsp70-mediated protection against stress, 
but recently new house-keeping roles of constitutively expressed Hsp70 proteins were 
discovered. This includes transport of proteins between different cellular 
compartments, degradation of unstable proteins, folding and refolding of proteins 
(103, 104). In addition to this very generalized role for Hsp70, they have been shown 
to regulate immune response via promoting of antigen processing and presentation 
(105-108) Hsp70 proteins are involved in chaperoning proteins/peptides during 
degradation and during antigen presentation via both MHC I and MHC II.  
In the antigen presentation via MHC I molecules Hsp70 protein was shown to 
physically associated with TAP, hence enabling efficient loading of chaperoned 
peptides onto MHC I molecules in the ER (105, 106, 109). Moreover, Hsp70 was 
shown to stabilize peptides after proteasomal degradation on their way to the ER 
(103). In the context of cross-presentation peptides chaperoned by Hsp were shown to 
be a necessary and sufficient source of antigen for efficient cross-priming of CD8+ 
T cells (106, 110). 
The importance of Hsp70 during MHC II presentation pathway was also clearly 
demonstrated (105, 111), however exact mechanism and location of its action is still 
under debate. One possibility is that Hsp70 assist in loading of peptides on MHC II in 
the MIIC. However it is not clear how soluble Hsp70 molecules access the vesicular 
MIIC compartments. Another possible role of these proteins in MHC II presentation is 
their help to deliver endogenous proteins during autophagy into lysosomes via 
LAMP-2 molecules (Fig. 1.18) (112). Yet, this mechanism still remains to be 
elucidated. 
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Figure 1.18 Heat shock proteins in antigen presentation, adapted from (105, 109, 
111)  
 
INTRODUCTION 
47 
 
5. CO-STIMULATORY MOLECULES 
 
Interaction between MHC/peptide/TCR only is not sufficient for efficient clonal 
activation and expansion of resting naive T cells.  For activation and acquisition of 
proper effector functions T cells require a second type of signal which is called co-
stimulation. Co-stimulatory molecules are expressed on surface of APCs and this 
signaling ensures, that T cells will respond properly to triggering of their TCR (113-
115). Co-stimulatory signals may exhibit both activating and inhibitory effect on T 
cells. Proper balance between those two opposite activities is necessary for induction 
of specific immune response as well as to maintain tolerance and prevent 
autoimmunity. Signals derived via co-stimulatory molecules are particularly important 
for naive T cells but they also play a role during activation of antigen experienced T 
cells (113-115). Below the most relevant co-stimulatory pathways for this work are 
described. 
 
CD80/CD86 – CD28/CD152 pathway is the best characterized T cell co-stimulatory 
pathway. Two members of the immunoglobulin-like B7 family CD80 (B7-1) and 
CD86 (B7-2) are expressed on cell surface of APCs and interact with the T cell 
associated co-receptors CD28 or CD152 (CTLA-4). This pathway is crucial for T cell 
activation as well as for maintenance of immunological tolerance. CD80 and CD86 
have highly overlapping functions, whereas CD28 on T cells transmits activating 
signals and CD152 delivers inhibitory signals (113-115).  
 
ICOS-ICOSL pathway appears to be particularly important for stimulating effector T 
cell responses and T cell dependent B cell responses, as well as in regulating T cell 
tolerance. ICOS (a member of the B7 family) has a unique function to regulate CD4+ 
T cell differentiation. ICOS expressing T cells were shown to secrete TH2 cytokines 
(IL-10, IL-4) (115) and ICOS-ICOSL signaling plays an important role in B cell 
differentiation, immunoglobulin class switching, germinal center formation and 
memory B cell development (115). ICOSL can be expressed on endothelial and 
epithelial cell as well as professional APCs (113-115). 
 
At the moment the B7 family of co-stimulatory molecules is still growing. In addition 
new functions for old family members are discovered (115). 
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CD40-CD40L pathway is crucial for induction effective T cell and B cell responses, 
additionally it facilitates the final maturation of APCs. CD40 and CD40L (CD154) 
molecules belong to the TNF and TNF receptor superfamily. Once CD4+ T cell will 
recognize antigen, they will rapidly up-regulate the expression of CD40L. Engagement 
of CD40 on the surface of APCs leads to production of IL-12 which is a potent inducer 
of TH1 immune response. Moreover, CD40-CD40L interaction leads to up-regulation 
of other co-stimulatory molecules, like CD80 and CD86. As consequence, APCs 
become more mature and can more efficiently prime T cells (1).  
 
Thus it becomes clear that a highly complex interaction involving a multitude of 
molecules, pathways and cell types is required to induce a proper and effective 
immune reaction that still requires major efforts to be fully understood.
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AIM   OF THE WORK 
Despite the multitude of potential pathogens that we constantly encounter, only very 
few are able to cause severe disease. The main reason for this is that our immune 
system is able in almost all cases to respond in an appropriate way. In these reactions 
T cells play a major role. However, T cells are not able to recognize a pathogen 
directly. Only processed fragments of pathogens are seen by the T cells. Thus, T cells 
need to be instructed by professional antigen presenting cells (APCs) like DCs, B cells 
or macrophages on the nature of the antigen i.e. they have to be imprinted to carry out 
the most appropriate effector function. To understand mechanisms underlying the 
initiation of such T cells responses many factors need to be consider. Thus, the 
environmental conditions where APCs develop and mature, their strategical location 
and cross-talk with other immune cells might play a major role as well as the overall 
systemic conditions of the organism like steady state conditions or inflammation. 
The aim of presented here work was therefore to investigate the influence of different 
developmental and environmental situations on the ability of splenic conventional DCs 
(cDCs) and MZ B cells to present antigen and induce T cell activation in steady state 
conditions.  In details: 
 
 Development, migration and maturation of DCs are strongly influenced by cytokines 
present in their environment. One class of such cytokines are type I IFNs. Since the 
role of type I IFNs during viral and bacterial infections as well as their influence on 
immune cells are well studied, I decided to investigate how constitutive levels of type 
I IFNs regulate cell mediated immunity. A few studies had shown spontaneous low 
level production of type I IFNs. It was proposed that these constitutive levels maintain 
cells in “primed” state enabling them rapid and robust response after encounter of a 
pathogenic stimulus. How these constitutive levels of type I IFNs might influence 
antigen presenting cells and the induction of adaptive immune responses was not 
known. Therefore in the present work I intended to characterize splenic cDCs from 
IFN-β or IFNAR deficient mice and to test them for antigen presentation and T cell 
stimulatory capacity. Additionally, I decided to establish the transcriptional program 
of such DCs by microarrays and possible conjunction with other proteins that are 
involved in antigen presentation. 
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 Development and function of splenic DCs are also influenced by the presence of other 
immune cells. Few studies showed that the presence of T and B cells is necessary for 
proper maturation of DCs and their ability to present antigen and stimulate T cells. 
Nevertheless, the reasons for this influence were so far not investigated in details. 
Hence, I wanted to characterize splenic cDCs from RAG-/- mice deficient in T and B 
cells and test them for their ability to present soluble and cell associated antigens. The 
analysis should include the transcriptional program of such DCs and how their lacking 
functions could be recovered.  
 
 Particular anatomical location of APCs, their access to antigens and interactions with 
effector cells can strongly influence the way and character of antigen presentation and 
therefore T cell differentiation. One example of a strategical location is the marginal 
zone (MZ) in the spleen and MZ B cells in particular. Detailed characterization of such 
cells revealed that they express the highest levels of the lipid presenting molecule 
CD1d among all splenic APCs. Thus, MZ B cells may play an important role in 
activation of invariant NKT cells, an effector cell type that is able to rapidly respond to 
antigen challenge. Therefore, I intended to test MZ B cells for their ability to present 
lipid antigens. The consequence of this presentation on differentiation of NKT cells in 
comparison to presentation by cDCs should also be investigated. 
 
This work should provide new insights first of all into how spontaneously produced 
type I IFNs ensures that DCs properly present antigens during steady state conditions. 
This could potentially influence maintenance of peripheral tolerance to self antigens. 
Then it should shed light on how character and specialization of DCs is imprinted by 
the presence of T and B cells during development and differentiation. Finally, it 
should provide clues how APCs of a particular anatomical location that has immediate 
access to antigen can dictate the outcome and character of immune response. 
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MATERIALS 
2.1 Mice 
Female wild type (WT) C57BL/6 mice were purchased from Harlan-Winkelmann 
(Borchem, Germany and AN Venvay, The Netherlands). 
Female IFN-β-/-(116), IFN-β+/+ controls, IFNAR-/- (117) C57BL/6 mice, OT I 
(transgenic for CD8+ T cells expressing a TCR specific to OVA257-264 peptide) and 
OT II (transgenic for CD4+ T cells expressing a TCR to OVA323-339 peptide) mice 
(118, 119), RAG1-/- (120) and RAG2-/- C57BL/6 (121) mice were bred at the animal 
facility of the Helmholtz Centre for Infection Research (HZI). 
The initial generation of Hsp70.1/3 knockout mice has been previously described 
(122). The C57BL/6 Hsp70.1/3-/- mice were backcrossed from a 129 background onto 
the C57BL/6 background and were raised at Washington University School of 
Medicine in St. Louis (kindly provided by Dr. Clayton Hunt and Prof. Tej K. Pandita). 
The Vα14 transgenic mice (123), C57BL/6 CD1d-/- (124) and C57BL/6  
β2microglobulin
-/- were kindly provided by Dr. Florian Winau (Max-Planck-Institute 
for Infection Biology, Berlin) and by Prof. H. Robson MacDonald (Ludwig Institute 
for Cancer Research, Lausanne, Switzerland). 
All mice were used between 8 to 12 weeks of age. Mice were bred and maintained in 
specific pathogen free conditions. Mouse care and experimental procedures were 
performed under approval of the local authority LAVES (Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit) 
 
2.2 Cell lines 
The B3Z T cell hybridoma (125) specific for the H-2·Kb/SIINFEKL complex was 
maintained in IMDM supplemented with 10% FCS, 100U/ml penicillin and 100µg/ml 
streptomycin, 50µM 2-mercaptoethanol, 2mM L-glutamine (complete IMDM). The 
hybridoma 25-D1.16 secreting an IgG1κ monoclonal antibody (mAb) specific for the 
pOV8·H-2Kb (126) was kindly provided by Dr Ronald Germain (NIH NIAID, 
Bethesda, USA). Antibody (Ab) was purified and conjugated with FITC according to 
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standard procedures. EG7-OVA cell line (127) (EL4 thymoma stably transfected with 
OVA cDNA, kindly provided by Prof. Michael Bevan, Scripps Clinics and Research 
Foundation, San Diego, USA) and EL4 cell line were maintained in complete IMDM. 
 
2.3 Antibodies and Fluorescence-Activated Cell Sorting (FACS) 
The following antibodies were used for flow cytometry: 
SPECIFICITY CLONE FLUOROCHROME COMPANY 
CD16/CD32 2.4G2 none BD Pharmingen 
CD11c N418 APC or PE-Cy7 eBioscience 
CD11b M1/70 PE-Cy7 or Pacific 
Blue 
eBioscience 
B220 (CD45R) RA3-6B2 APC-AlexaFluor 750  
or APC-Cy7 
eBioscience  
or BD Pharmingen 
CD4 GK1.5 PE eBioscience 
CD8α 53-6.7 Pacific Blue, FITC 
 or PE 
eBioscience 
H-2Kb Y-3 FITC Self purified and  
conjugated 
I-Ab M5/114.15.2 FITC eBioscience 
CD1d 1B1 PE eBioscience 
NK1.1 PK136 FITC, PE-Cy7 or 
PerCP-Cy5.5 
Self purified and  
conjugated, 
eBioscience,  
CD49b Dx5 PE-Cy7 or PE eBioscience 
CD19 1D3 APC BD Pharmingen 
CD21/35 7G6 FITC or biotin BD Pharmingen, self 
purified and conjugated 
CD5 53-7.3 FITC, PE  BD Pharmingen, 
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CD23 B3B4 PE or biotin eBioscience 
CD80 16-10A1 PE eBioscience 
CD86 GL-1 FITC eBioscience 
CD28 37.51 APC eBioscience 
CTLA-4 UC10-4B9 PE eBioscience 
CD40 HM40-3 FITC eBioscience 
CD40L MR1 PE eBioscience 
ICAM-1 YN1/1.7.4 PE eBioscience 
ICOS 7E.17G9 none or PE-Cy5 eBioscience 
ICOSL HK5.3 none or PE eBioscience 
GITR DTA-1 none or PE eBioscience 
GITRL eBioYGL386 biotin eBioscience 
B7-H1 MIH5 PE eBioscience 
B7-H4 eBioMIH29 PE eBioscience 
B7-DC TY25 biotin eBioscience 
PD-1 RMP1 PE eBioscience 
OX40 OX-86 PE eBioscience 
OX40L RMI134L biotin BD Pharmingen 
CD27 LG.7F9 biotin eBioscience 
CD70 FR70 PE eBioscience 
CD48 HM48-1 FITC eBioscience 
CD244.2 eBio244F4 PE eBioscience 
H2-Kb/SIINFEKL 25-D1.16 FITC or APC Self purified 
and conjugated or 
eBioscience 
IL-4 11B11 PE BD Pharmingen 
IFN-γ XMG1.2 Pacific Blue eBioscience 
IL-17 17B7 AlexaFluor 647 eBioscience 
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IL-13 eBio13A AlexaFluor 647 eBioscience 
 Mouse IgG Isotype  
control 
none Dianova 
Mouse IgM, κ Isotype  
control 
none BD Pharmingen 
IL-12 C17.8 none eBioscience 
 
Flow cytometry analysis was performed using FACSCanto, LSRII (BD Bioscience), 
sorting was performed using FACSAria I and FACSAria II (BD Bioscience). The data 
were analyzed using FACSDiva (BD Bioscience) software, version 6.1. 
 
2.4 Preparation of cell associated ovalbumin (OVA) 
EG7-OVA and EL4 (control, non-transfected cells) cells were harvested from culture 
bottles and counted. Further 1×106 cell were UV irradiated, using an UV Crosslinker, 
with 9mJ/cm2. Next, cells were washed intensively with PBS and used in antigen 
presentation assay (described in “Methods”). 
 
2.5 Biotinylation of OVA 
Soluble OVA (EndoGrade OVA, Profos) (2mg/ml) dissolved in 0.1M NaHCO3 buffer, 
pH 8.2, was incubated with 50µg of biotin ester for 1h with continuous stirring, 
followed by dialysis against PBS. 
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METHODS 
2.6 Isolation of splenocytes 
Spleen cells were prepared by gentle flushing out the spleens with complete IMDM. 
Erythrocytes were lysed for 2 min in ACK buffer (0.15M NH4Cl, 10mM KHCO3, 
0.1mM EDTA) and washed two or three times in PBS. Cell clumps were removed by 
passage through a 50µm nylon filter. Splenocyte preparation was carried out strictly 
on ice. Cells were further used for staining with different Abs, FACS analysis or 
FACS sorting. 
 
2.7 Staining of splenocytes and cell sorting strategy 
Single cell suspensions were treated with anti-mouse CD16/CD32 BD Fc Block for 10 
min followed by staining with appropriate Abs for 20 min on ice. Further cells were 
washed with PBS. 
Splenic cDCs were sorted as cells with high side scatter (SSChi (high)) that were: 
 CD11chi, CD8α+/-, CD11b+/-, B220- 
All B cells were gated on CD19 and were positive for following markers: 
CD21/35hi, CD23-/lo(low) (MZ B cells) 
CD21/35lo, CD23+, CD5lo (B1 B cells) 
CD21/35lo, CD23+, CD5- (B2 B cells) 
Invariant NKT cells first were enriched by magnetic depletion of B cells and CD8 
positive cells (Invitrogen). Next, cells were stained and sorted as follows: 
NKT cells were negative for lineage markers (lin-),  
like CD8α-, B220-, CD11c-, CD49b-, CD11b- (prepared as a lin- coctail)  
and positive for NK1.1+, CD4+, TCRα/β+, CD3+ 
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Final purity of all APCs was always >97%. Final purity of NKT cells was always 
above 99% and did not contain any CD11chi cells. All samples during the sorting 
procedure were kept at 4oC. 
 
2.8 Preparation of T cells 
OT I (OVA specific CD8+ T cells) and OT II (OVA specific CD4+ T cells) were 
isolated from lymph nodes (subcutaneous and mesenteric) and spleen. Single cell 
suspensions were further purified using the CD8 or CD4 negative isolation kits 
(Dynal) containing Abs against B220, CD11b, Ter-119, CD16/32 and CD4 (for OT I 
isolation) or CD8 (for OT II isolation) following the protocol provided by the 
manufacturer. Cell preparations contained more than 90% of the desired cell 
population and were essentially free of CD11chi cells as determined by flow cytometry 
using Abs specific for CD4 or CD8 and CD11c, respectively. For antigen presentation 
assays OT I or OT II cells were stained with 1µM CFSE (Molecular Probes) for 10 
minutes at 37oC according to the manufacturer’s protocol. 
 
2.9 Analysis of antigen presentation in vitro and ex vivo (CFSE dilution assay) 
For the experiments using soluble OVA or peptides, individual APCs populations 
were plated in 96-well plates (Nunc) at 1x104 cells per well with the indicated amount 
of soluble EndoGrade OVA (Profos), OVA257-264 (SIINFEKL, Ana Spec Inc.) or 
OVA323-339 (kindly provided by Dr. W. Tegge, HZI) for 1h at 37
oC in complete 
IMDM. The cells were further washed three times and resuspended in complete 
IMDM containing 2x105 CFSE labeled OT I or OT II cells. Proliferation of T cells 
was analyzed by flow cytometry after 1.5 (OT I peptide) or 2.5 days of culture. Cells 
were stained with anti-CD4 or anti-CD8 Abs for 20 minutes, washed and resuspended 
in 200 µl of PBS containing Cy5-labeled 0.6µm latex beads to normalize cell numbers. 
Samples were analyzed until 2x104 beads were collected. The number of divided cells 
(propidium iodidelo, CFSElo, CD4+ or CD8+) was determined as described (128). For 
ex vivo experiments mice were injected intravenously with 1mg of OVA or 1mg of 
OVA together with 200µg poly I·C (Fluka). 24h later mice were sacrificed, APCs were 
sorted and incubated with OT I or OT II cells for 2.5 days. In some experiments 
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murine recombinant IFN-β (R&D Systems) was added to the cultures of T cells and 
APCs.  
 
2.10 Determination of antigen uptake and processing 
Sorted DCs were incubated with 62.5µg/ml of DQ-OVA (Molecular Probes) for 45 
min at 37oC or on ice. DCs were then washed carefully and analyzed by FACS. For 
analysis of uptake of OVA-Cy5 soluble OVA was conjugated to PE-Cy5. The labeling 
procedure involved gel filtration as a final step for removal of low molecular mass 
molecules such as unbound fluorochrome. The concentration of OVA-Cy5 was 
determined by measurement of OD280. Sorted DCs were incubated with indicated 
concentrations of OVA-Cy5 for 1h, than washed carefully. Uptake of fluorescent 
OVA was determined by FACS. 
 
2.11 B3Z colorimetric assay 
Sorted splenic cDCs (104cells/well) were pulsed for 1 h with various concentrations of 
SIINFEKL peptide, washed twice and resuspended in phenol-red free RPMI (Gibco) 
containing 100U/ml penicillin and 100µg/ml streptomycin, 1% FCS and 2mM 
L-Glutamine. DCs were then co-cultured in a 96-well U bottomed plate with 5x104 
B3Z cells/well overnight at 37oC (B3Z cells expresses β-galactosidase of E.Coli under 
the promoter of IL-2). Next day 150µl of supernatant was taken from each well and 
replaced with 150µl of PBS containing 5mM ONPG (Sigma) and 0.5% IGEPAL-20 
(Sigma). The plate was than incubated at 37oC for 2 h and optical density was 
measured at 450 nm with wavelength correction set at 650 nm. 
 
2.12 In vitro NKT cell proliferation assay 
For the testing of NKT cells proliferation and activation, APC (cDCs and MZ B cells) 
were loaded with 1µg/ml or graded concentrations of α-galactosylceramide (αGalCer). 
αGalCer (Alexis Biochemicals) was not removed during the assays. Sensitized APCs 
(5x104) were incubated with 5x104 CFSE labeled NKT cells for 16h or 2.5 days on 
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96-well U bottomed plates. For the last 4 hours of incubation, Brefeldin A was added 
to block protein secretion. First, cultured supernatants were collected to test 
concentration of secreted cytokines. Further, cells were stained intracellularly for IL-4 
and IFN-γ. The number of divided cells (propidium iodidelo, CFSElo, NK1.1+) was 
also determined. In some experiments anti-IL-12 (10µg/ml), anti-GITR (10µg/ml), 
anti-ICOSL (10µg/ml) Abs and IgG isotype control (10µg/ml) were added into the 
APCs/NKT cells co-cultures. In one approaches mice were injected i.v. with an anti-
CD40 Ab (150µg/mouse) for 4 hours. 
 
2.13 In vivo NKT cell activation assay 
For in vivo testing of NKT cell activation and cytokine production by MZ B cells and 
cDCs, APCs were sorted as described above, loaded ex vivo with 2µg/ml of αGalCer 
for 45 min and washed extensively. Further 5×105 of antigen loaded MZ B cells or 
cDCs were injected i.v. into CD1d-/- recipient mice together with purified NKT cells 
(1×107). As a control untreated MZ B cells and cDCs were injected with together with 
NKT cells. After 16h spleens of recipient mice were removed, splenocytes were 
isolated and incubated for 4h with Brefeldin A (25µg/ml) (Sigma). Further cells were 
stained intracellularly for IL-4 and IFN-γ.  
 
2.14 Intracellular staining of cytokines 
After 16h or 2.5 days co-culture of APCs and NKT cells, cells were incubated for the 
last 4 h with 25µg/ml of Brefeldin A (Sigma) or for 2h with PMA/Ionomycin and than 
2h with Brefeldin A for ex vivo experiments. Further, cells were stained for NK1.1, 
CD11c (when cDCs were used as APCs) or B220 (when MZ B cells were used as 
APCs), fixed and permeablized according to manufacturer protocol 
(Cytofix/Cytoperm kit, BD) next stained for intracellular IFN-γ Pacific Blue, IL-4 PE. 
 
 
 
MATERIALS  AND  METHODS 
61 
 
2.15 Intracellular staining of Hsp70 
Splenic cDCs were sorted and stained intracellularly using Cytofix/Cytoperm kit (BD 
Pharmingen) according to manufacturer’s protocol with anti-Hsp70 (C92F3A-5) PE 
conjugated Ab (Stressgen). 
 
2.16 Presentation of cell associated OVA by RAG-/- cDCs 
Splenic cDCs from WT and RAG-/- mice were as described above. Further, they were 
plated on 96-well plates (1×104/well) together with UV-irradiated EG7-OVA or EL-4 
cells (1×104) and after 1h OT I CFSE labeled cells were added. Proliferation of T cells 
was assessed after 2 days, according to the protocol described for soluble OVA. 
 
2.17 Inhibition of Hsp70 by 15-deoxyspergualin (DSG) 
DSG was a generous gift of Nippon Kayaku Co. Ltd. (Tokyo, Japan). Animals were 
injected intraperitoneally daily with 10mg/kg of DSG or PBS for 6 days before splenic 
cDCs were sorted and tested for their antigen presentation capacity with OT I or OT II 
cells in CFSE dilution assays. 
 
2.18 Quantitative real-time PCR 
Total RNA was extracted from sorted APCs using the RNeasy mini kit (Qiagen) 
according to the manufacturer’s instructions. DNA contamination in the total RNA 
preparation was eliminated using DNase I (Qiagen). Oligo(dT)18 primers and 
RevertAidTM First Strand cDNA Synthesis kit (Fermentas) was used for reverse 
transcription of purified RNA. All gene transcripts were quantified by quantitative 
PCR with Power SYBR Green qPCR Master Mix (Applied Biosystems) and the Light 
Cycler apparatus (ABI PRISM Cycler Applied Biosystems).  
 
Primers were used as follows: 
RPS9 primers: 
Sense, 5’-CTGGACGAGGGCAAGATGAAGC-3’  
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Anti-sense, 5’- TGACGTTGGCGGATGAGCACA-3’ 
Hsp70.1 primers (129): 
Sense, 5’-AGGTGCTGGACAAGTGCCAG-3’  
Anti-sense, 5’-AACTCCTCCTTGTCGGCCA-3’  
C1qa primers: 
Sense, 5’- ATGGACAGTGGCTGAAGATG-3’ 
Anti-sense, 5’- AAAACCTCGGATACCAGTCC-3’ 
C1qb primers:  
Sense, 5’- GGTTCCTGGCTCTGATGG-3’ 
Anti-sense, 5’- GGTCCCCTTTCTCTCCAAAC-3’ 
 
2.19  Microarray studies 
RNA isolation, cDNA preparation and DNA microarray analysis of gene expression 
was performed at the gene array facility of the HZI. Fluorescent images of hybridized 
microarrays (Affymetrix, MOE-430 version 2.0) were obtained using an Affymetrix 
Genechip Scanner. Microarray data were analyzed using BioConductor Suite 2.1 
software. All samples were repeated two times with individually sorted cells and 
averaged. Data discussed here have been deposited in NCBI’s Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO 
series accession number GSE12392. 
Data concerning RAG-/- cDCs are accessible through following link: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tpulxgoekcgysxy&acc=GSE17
989 
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2.20  Western blot for degradation of OVA 
Splenic cDCs (at least 5×105 per sample) were sorted from WT and RAG-/- mice. Cells 
were loaded with OVA-bio for 1h, washed extensively, lysed in RIPA buffer (100mM 
Tris HCl, 150mM NaCl, 1% IGEPAL-20, 0.3mM PMSF) buffer in the presence of 
proteases inhibitor coctail, centrifuged and boiled for 5 min in the presence of 
2-mercaptoethanol. Further samples were subjected to 10% SDS-PAGE followed by 
transfer to polyvinylidene difluoride (PVDF) membranes (Millipore). Blocking of 
membranes was performed in SuperBlock (Pierce) to avoid endogenous biotin 
contamination present in milk. Whole OVA as well as degradation products were 
detected by streptavidin conjugated with horsreadish-peroxidase (BD Pharmingen). As 
a control, membranes were incubated with rabbit anti-actin (Sigma) primary Ab, 
followed by incubation with secondary anti-rabbit Ab conjugated with horsreadish-
peroxidase (Sigma). All Abs were diluted in SuperBlock. The blots were developed 
with an enhanced chemiluminescence method (advanced ECL kit, Amersham 
Biosciences). Chemiluminescence was detected using the ChemiDoc XRS system 
(Bio-Rad).  
 
2.21  In vivo treatment with antibodies 
To examine the influence of soluble antibodies like IgM and IgG on the function of 
RAG deficient splenic cDCs, WT and RAG-/- mice were i.v. injected with 75μg/ml of 
IgM (BD Pharmingen), 75μg/ml IgG (Dianova), IgM+IgG (75μg/ml+75μg/ml) or PBS 
on day 0 and day7. After 21 days mice were sacrificed and splenic cDCs were sorted. 
The cells were loaded with soluble OVA and used as APCs in OT I assays. 
Proliferation of T cells was determined as mentioned before. 
 
2.22  ELISA 
ELISA was used for the detection and quantification of cytokines secreted by activated 
NKT cells in culture supernatants. Anti IFN- and IL-4 ELISA kits were purchased 
from Becton Dickinson and performed according to manufacturer protocol. 
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2.23 Annexin V staining 
Staining was performed according to manufacturers protocol (BD Pharmingen, FITC 
Annexin V apoptosis kit). Briefly, 1×105 splenocytes isolated from RAG-/- or WT 
mice were resuspended in 1×Binding Buffer (BD), incubated for 15 min at RT with 
Annexin V (BD) in the presence of PI. Further samples were diluted with 1×Binding 
Buffer and analyzed by flow cytometry 
 
2.24  Reconstitution of RAG deficient mice with B cells 
WT and RAG deficient mice were injected i.v. with 5×106/mouse freshly sorted WT 
CD19+ splenic B cells. 21 days after reconstitution splenic cDCs were sorted from 
recipient mice and used as APCs in OT I antigen presentation assay. Proliferation of 
T cells was determined as mentioned before. 
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ABSENCE OF IFN-β IMPAIRS ANTIGEN PRESENTATION CAPACITY OF 
SPLENIC DENDRITIC CELLS VIA DOWN-REGULATION OF HSP70 
[published in The Journal of Immunology 2009, July 15; 183(2): 1099-109] 
Type I interferons (IFNs) play a key role in linking the innate and adaptive arms of the 
immune system. Although produced rapidly in response to pathogens, IFNs are also 
produced at low levels in the absence of infection. In the present study I demonstrate 
that constitutively produced IFNs are necessary in vivo to maintain dendritic cells 
(DCs) in an “antigen presentation competent” state. Conventional dendritic cells 
(cDCs) isolated from spleens of IFN-β or IFNs receptor (IFNAR) deficient mice 
exhibit a highly impaired ability to present antigen and activate naive T cells. In the 
absence of both IFN-β and IFNAR receptor I detected a lower number of specific 
MHC/peptide complexes at the surface of splenic cDCs. Microarray analysis of 
mRNA isolated from IFN-β-/- and IFNAR-/- cDCs revealed diminished expression of 
two genes that encoded members of the heat shock protein 70 (Hsp70) family, which 
are required for efficient generation of stable MHC/peptide complexes expressed on 
the cell surface of cDCs.  Consistent with this observation, pharmacological inhibition 
of Hsp70 in cDCs from wild type (WT) mice impaired their T cell stimulatory 
capacity. Similarly, the antigen presentation ability of splenic cDCs isolated from 
Hsp70.1/3-/- mice was also severely impaired in comparison to WT cDCs. Thus, 
constitutive IFN-β expression regulates Hsp70 levels in order to help maintain DCs in 
a competent state for efficient priming of effector T cells in vivo.  
 
3.1  Splenic dendritic cells from IFN-β-/- and IFNAR-/- mice are impaired in T cell 
stimulation 
IFNs are known to be constitutively produced at low levels under non-inflammatory 
conditions (16). To study the influence of IFNs on antigen presentation under 
physiological conditions I decided to focus on freshly isolated splenic cDCs. These 
cells are representative of typical non migratory DCs found in vivo at steady state (47, 
51, 130). Analyzing IFN-β and IFNAR deficient mice, I detected no differences with 
regard to percentage of various splenic cDCs subpopulations in mice with and without 
either IFN- or IFNAR (Fig. 3.1A). Furthermore, I determined the overall number of 
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leukocytes in several lymph nodes and spleen. Consistently, there was no significant 
difference observed in comparison to WT mice (Fig. 3.1B).  
Thus, I analyzed the ability of cDCs exhibiting the markers CD11chi, CD11b+/-, 
CD8α+/-, B220- from spleens of WT, IFN-β-/- and IFNAR-/- mice to present ovalbumin 
(OVA) protein to CFSE labeled OT I or OT II T cells according to the protocol 
displayed in Scheme 3.1. When compared to WT, cDCs from IFN-β-/- and IFNAR-/- 
mice were severely impaired in their ability to activate such CD8+ and CD4+ T cells 
(Fig. 3.2A and 3.2C).  
To test whether the anomaly associated with IFN-β or IFNAR deficiency affects also 
the presentation of preprocessed antigen, i.e. peptides, cDCs from WT, IFN-β-/- and 
IFNAR-/- mice were loaded with MHC class I or MHC class II specific peptides 
(OVA257-264 (SIINFEKL) and OVA323-339, respectively) and then incubated with CFSE 
labeled OT I and OT II T cells. As shown in Fig. 3.2B and 2D, T cell stimulation was 
also highly impaired when peptide loaded cDCs from IFN-β-/- and IFNAR-/- mice were 
used.  
Throughout most of these experiments, I used bulk sorted splenic cDCs because 
during in vitro co-cultures with T cells the two distinct populations - CD8α+ DCs and 
CD8α- DCs (myeloid DCs) from IFN-β-/- and IFNAR-/- mice were similarly impaired 
in their T cell stimulatory capacity compared to WT DCs (Fig. 3.3). 
IFN-β-/-
IFNAR-/-
WT
OT I or OT II 
transgenic
mice
CFSE labeled
CD8+ or CD4+ T 
cells
Loading with OVA 
protein or
peptides
Sorted
splenic
cDCs
Incubation of cDCs with
transgenic T cells
Measurement of T cell
proliferation
 
Scheme 3.1 In vitro antigen presentation assay to test the T cell stimulatory capacity of cDCs from mice 
defective in the type I IFN system 
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Figure 3.1 Similar percentage and frequency of different splenic cDCs populations, macrophages 
and granulocytes in spleens of WT, IFN-β-/- and IFNAR-/- mice. (A) Splenocytes from WT, IFN-β-/- 
and IFNAR-/- mice were isolated and stained for following markers: CD11c, CD11b, CD4, CD8α and 
B220 and analyzed by flow cytometry. (B) Similar number of leukocytes per lymph node or spleen in 
WT, IFN-β-/- and IFNAR-/- mice. Data are representative of three independent experiments with at least 
five mice per group. 
  
A 
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Figure 3.2 Splenic conventional dendritic cells (cDCs) from IFN-β-/- and IFNAR-/- mice are 
impaired in their antigen presentation capacity of soluble OVA as well as OVA derived peptides 
in the context of both MHC I and MHC II. The purified OT I or OT II transgenic T cells were 
labeled with CFSE and incubated for 1.5 days (OT I peptide) or 2.5 days with splenic cDCs (CD11chi, 
CD11b+/-, CD8α+/-, B220-) in ratio 10:1. cDCs from C57BL/6 WT, IFN-β-/- and from IFNAR-/- mice 
were preloaded with OVA257-264 (class I-restricted), OVA323-339 (class II-restricted) peptides or whole 
OVA protein for 1h and further were washed intensively. (A and B) Antigen presentation in the context 
of MHC II, (C and D) Antigen presentation in the context of MHC I. OVA concentration 250g/ml, 
OVA257-264 peptide concentration 10ng/ml. The proliferative response of T cells was enumerated by 
flow cytometry. Data are representative of at least three mice for WT, IFN-β-/- and IFNAR-/- in multiple 
independent experiments. Statistical significance was determined using the paired Student’s t test. 
* P<0.05; ** P<0.01; *** P<0.005 
A B 
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Figure 3.3 Two distinct populations of splenic conventional DCs (cDCs) – CD8α+DCs and CD8α-
DCs from IFN-β-/- and IFNAR-/- mice are similarly impaired in their ability to activate naive T 
cells in comparison to WT DCs. The purified OT I or OT II transgenic T cells were labeled with CFSE 
and incubated for 1.5 days (OT I peptide) or 2.5 days with splenic CD8α+DCs (CD11chi, CD11b+, 
CD8α+, B220-) or CD8α-DCs (CD11chi, CD11b-, CD8α+, B220-)  in ratio 10:1. Both DCs populations 
from C57BL/6 WT, IFN-β-/- and from IFNAR-/- mice were preloaded with OVA257-264 (class 
I-restricted), OVA323-339 (class II-restricted) peptides or whole OVA protein for 1h and further were 
washed intensively. (A and B) Antigen presentation in the context of MHC I, (C and D) Antigen 
presentation in the context of MHC II. OVA concentration 250g/ml (MHC I), OVA concentration 
500g/ml (MHC II), OVA257-264 peptide concentration 10ng/ml, OVA323-339 peptide concentration 
2g/ml. The proliferative response of T cells was enumerated by flow cytometry. Data are 
representative of at least three mice for WT, IFN-β-/- and IFNAR-/- in three independent experiments. 
Statistical significance was determined using the paired Student’s t test. * P<0.05; ** P<0.01; 
*** P<0.005 
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3.2 Deficiency in IFNs does not impair survival of cDCs in vitro 
As IFNs provide cellular survival signals under certain conditions (26, 131), I first 
wanted to test whether the reduced ability to stimulate T cells might be due to lower 
survival of cDCs from IFN-β-/-or IFNAR-/- mice during the in vitro T cell stimulation 
assay. Splenic cDCs sensitized with OVA protein were incubated with OT I or OT II 
cells. After 16 and 32 hours the percentage of live cDCs was assessed by propidium 
iodide (PI) exclusion. WT, IFN-β-/- and IFNAR-/- cDCs were equally viable under 
these conditions (Fig. 3.4A, 3.4B). Thus, the reduced ability to stimulate T cells in 
vitro was not due to lower survival of IFN-β-/- cDCs. 
 
Figure 3.4 Impaired antigen presentation capacity of splenic cDCs from   IFN-β-/- mice is not due 
to their impaired viability. Survival of splenic cDCs from WT and IFN-β-/- mice during incubation 
with (A) OT I or (B) OT II cells. Splenic cDCs from WT and IFN-β-/- mice were loaded with OVA 
protein (250µg/ml OVA for OT I and 500µg/ml OVA for OT II), washed and incubated with transgenic 
T cells for 16h and 32h. In indicated time points cells were collected, stained for CD11c, CD11b, CD8α 
and B220. Percentage of live CD8α+DC or CD8α-DCs was appointed by PI exclusion. Data are 
representative of at least three mice for WT and IFN-β-/- in two independent experiments. 
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3.3 Impaired stimulatory capacity of cDCs can be restored by supplementation with 
recombinant IFN-β in vitro or induction of IFNs with poly I·C in vivo 
Next, I asked whether exogenous administration of IFNs could restore the impaired T 
cell stimulatory capacity of IFN-β-/- cDCs in vitro. Titration of murine recombinant 
IFN-β (rIFN-β) into co-cultures of IFN-β-/- cDCs and T cells showed that low amounts 
(0.1U/ml) could completely restore the impaired T cell stimulatory function 
(Fig. 3.5A). However, probably due to activation of negative feedback mechanisms, 
addition of higher concentrations of rIFN-β (5-500U/ml) to the co-cultures failed to 
restore T cell stimulatory ability of cDCs (Fig. 3.5A and data not shown). These 
results support the argument that the low levels of IFN-β produced at steady state are 
well optimized for maintaining of cDCs in antigen presentation competent state. 
Nevertheless, in such a situation it is difficult to exclude that exogenous rIFN-β 
influenced T cell proliferation. A direct effect of IFNs on T cells has been well 
documented (24, 26) although it only partially could explain my results. I could show 
that IFNAR-/- cDCs which are able to produce IFN-β (data not shown), are still 
inefficient in activating a T cell response (Fig. 3.2). In addition, when such co-cultures 
are complemented with recombinant IFN-β the inefficiency of T cell activation 
remained (Fig. 3.5B). This clearly demonstrates that steady state production of IFN-β 
is required for maintenance of proper cDC function.  
Furthermore, I tested whether triggering IFNs-α in vivo could compensate the impaired 
development of T cell stimulatory capacity of cDCs from IFN-β-/- mice. WT, IFN-β-/- 
and IFNAR-/- mice were intravenously (i.v.) injected with OVA alone or OVA 
together with polyinosinic-polycytidylic acid (poly I·C) a well known stimulator of 
IFNs. After 24h, splenic cDCs were sorted and tested for their ability to activate the 
proliferation of OT I or OT II T cells. Data depicted in Fig. 3.5C show that IFNs-α 
induction by poly I·C compensated for the lack of IFN-β during cDC development in 
vivo and partially recovered their function. As expected, in vivo administration of poly 
I·C did not improve the stimulatory function of splenic cDCs from IFNAR-/- mice as 
they are completely unresponsive to IFNs signaling (Fig. 3.5D).  
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Figure 3.5 IFN-β is required in vitro during cDC-T cell contact as well as in vivo during cDCs 
development. (A) Addition of low amounts of murine recombinant IFN-β (0.1U/ml) leads to efficient 
recovery of impaired ability to present antigen by splenic cDCs from IFN-β-/- mice. OT I and OT II cells 
after purification were labeled with CFSE. Splenic cDCs from WT and IFN-β-/- mice were sorted out 
from spleens of at least three mice, loaded with indicated concentration of OVA peptide for 1h, washed 
intensively and co-cultured with T cells for 2.5 days in presence of recombinant murine IFN-β. (B) 
Enhanced proliferation of T cells accompanying impaired function of IFNAR-/- cDCs in the presence of 
exogenously added low amounts of rIFN-β. Splenic cDCs from WT and IFNAR-/- mice were sorted out 
from spleens of at least three mice per group, loaded with 250µg/ml of OVA protein for 1h, washed 
intensively and co-cultured with OT I T cells for 2.5 days in presence of 0.1U/ml of recombinant 
murine IFN-β. (C and D) In vivo induction of IFNs by poly I·C leads to partial restoration of function of 
splenic cDCs from IFN-β-/- mice. WT, IFN-β-/- and IFNAR-/- mice were treated with poly I·C together 
with OVA or OVA alone, 24h later splenic cDCs were sorted out and incubated in vitro with CFSE 
labeled OT I or OT II cells for 2.5 days. The proliferative response of T cells was enumerated by flow 
cytometry. Data are representative of two independent experiments.  
 
I also tested the T cell stimulatory capacity of DCs differentiated in vitro by incubating 
bone marrow cells with IL-4 and GM-CSF (BMDCs). After 8 days of culture I 
obtained around 80% CD11c positive cells from WT, IFN-β-/- and IFNAR-/- mice. 
Here, WT and IFN-β-/- or IFNAR-/- BMDCs were comparable in their ability to 
stimulate the proliferation of T cells (data not shown). This suggests that the influence 
C D 
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of IFNs observed ex vivo is greatly dependent on the overall stimulatory context under 
which the DCs develop. 
 
3.4 IFN-β-/- and IFNAR-/- cDCs display normal antigen capture and processing 
A differential ability to acquire and process soluble antigen could account for the 
diminished stimulatory capacity of cDCs in the absence of the IFNs system. Therefore, 
the efficiency of splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice to take up and 
degrade soluble OVA was assessed. I used DQ-OVA, which generates fluorescent 
byproducts upon degradation (Scheme 3.2). As shown in Fig. 3.6, splenic cDCs from 
all groups acquired and generated comparable amounts of fluorescent DQ-OVA 
products. This was true for different DQ-OVA concentrations tested (data not shown). 
Thus, changes in antigen uptake and degradation could not account for the impaired T 
cell stimulatory capacity of cDCs from IFN-β-/- or IFNAR-/- mice. 
DQ-OVA self quenched
conjugate of OVA and pH
insensitive dye BODIPY®FL
PROTEOLYSIS
Fluorescent degradation
products
 
Scheme 3.2 Mechanism of action of DQ-OVA, results presented on Fig. 3.6. 
 
Figure 3.6 Lack of IFN-β and IFNs signaling has no influence on proper uptake and processing of 
soluble antigen by splenic cDCs. Splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice were sorted out 
and incubated for 1h with 62.5µg/ml of DQ-OVA. Further cells were washed and BODIPY 
fluorescence was measured using flow cytometry. Density plots show DQ-OVA proteolysis by splenic 
cDCs. Data are representative of three independent experiments and of at least three mice per group. 
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3.5 Similar expression of MHC and co-stimulatory molecules on cDCs from WT, 
IFN-β-/- and IFNAR-/- mice 
The maturation status of DCs is known to be a fundamental factor for proper T cell 
stimulation. One of the mechanisms by which constitutive IFNs signaling could 
influence T cell stimulation is to enhance expression of MHC or adhesion and co-
stimulatory molecules on the surface of DCs (21). However, analysis of splenic CD8α+ 
and CD8α- cDCs for MHC I and MHC II as well as co-stimulatory or adhesion 
molecules like CD86, CD80, CD40 and ICAM-1 indicated no significant differences 
between WT, IFN-β-/- and IFNAR-/- mice in both cDC populations (Fig. 3.7). 
Therefore, the impaired function of splenic cDCs from IFN-β and IFNAR deficient 
mice was not due to lower expression of such surface molecules. 
 
 
 
 
Figure 3.7 Similar surface phenotype of splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice. Please 
see description on the next page. 
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Figure 3.7 Similar surface phenotype of splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice. 
Splenocytes isolated from C57BL/6 WT, IFN-β-/- or IFNAR-/- mice were stained and gated on the basis 
of CD11c, CD11b, CD8α and B220 on two populations of cDCs. Graphs show MFI (Mean 
Fluorescence Intensity) values for expression of indicated markers. MFI of each marker was measured 
for at least three mice per group.  Data are representative of five independent experiments. 
 
3.6 An intact IFNs system is required for the efficient formation of stable 
MHC/peptide complexes at the surface of splenic cDCs 
 
The fact that an impaired T cell stimulatory capacity of cDCs from IFN-β-/- and 
IFNAR-/- mice was also found for the presentation of peptides, not requiring further 
processing, as well as unimpaired DQ-OVA degradation suggested that the phenotype 
of IFN-β-/- and IFNAR-/- cDCs was most likely due to a defect in peptide presentation 
rather than antigen processing steps. Therefore, I decided to study the MHC/peptide 
complexes on the surface of cDCs. I employed B3Z cells, a H-2·Kb restricted T cell 
hybridoma specific for the OVA epitope SIINFEKL (OVA257-264), which upon T cell 
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receptor (TCR) activation expresses β-galactosidase (125). The activation of B3Z 
cells, being a hybridoma, is independent of co-stimulation (132). Thus, their activation 
should only be dependent on the concentration of MHC I/peptide complexes 
recognizable by the TCR. Splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice were 
loaded with OVA257-264 peptide and tested for their ability to activate B3Z cells 
(Scheme 3.3). As shown in Fig. 3.8A and 3.8B, cDCs from mice deficient in IFN-β or 
IFNAR exhibited lower stimulatory capacity. These results confirmed that the 
impaired function of splenic cDCs from such mice is not due to lower levels of co-
stimulatory molecules, but strongly suggested that the defect was in the process of 
MHC I/peptide complex formation. By using the 25-D1.16 antibody which recognizes 
SIINFEKL bound to the H-2·Kb molecule, according to the Scheme 3.4 (126), I 
confirmed this interpretation. DCs from either IFN-β-/- or IFNAR-/- mice had lower 
levels of MHC I/SIINFEKL complexes compared to cDCs from WT mice (Fig. 3.8C). 
 
IFN-β-/-
IFNAR-/-
WT
Sorted 
splenic 
cDCs
Loading with OVA 
peptide
B3Z hybridoma T cells 
recognizing MHC I/SIINFEKL 
(OVA257-264) peptide 
complexes
Incubation of cDCs with  B3Z T cells
Activation of B3Z T cells Production of β-galactosidase
Addition of β-galactosidase substrate 
ONPG (colorless)
Reaction product  ortho-nitrophenol 
(yellow) +galacotse
Measurement 
OD450/650  
 
Scheme 3.3 Activation of B3Z hybridoma T cells, results on Fig. 3.8A, B. 
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Figure 3.8 (A, B) Splenic cDCs from IFN-β-/- and IFNAR-/- mice form lower levels of MHC 
I/SIINFEKL complexes. Splenic cDCs were sorted out from spleens of WT, IFN-β-/- or   IFNAR-/- 
mice, pulsed with SIINFEKL peptide (OVA257-264) for 1h, washed intensively and (A, B) Co-cultured 
with the SIINFEKL/H-2Kb restricted B3Z hybridoma T cells for 24h. Cells were then lysed and 
monitored for LacZ expression by the introduction of ONPG substrate. Optical density was measured at 
450nm with wavelength correction set at 650 nm. Results are representative of at least three mice for 
WT, IFN-β-/- and IFNAR-/- in three independent experiments. Statistical significance was determined 
using the paired Student’s t test. * P<0.05; *** P<0.005 
 
 
Dendritic cell
MHC I
FITC
FITC
FITC
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MHC I/SIINFEKL 
complex
OVA257-264 (SIINFEKL) 
peptide
 
 
Scheme 3.4 Staining with 25-D1.16 monoclonal antibody, results on Fig. 3.8C. 
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Figure 3.8 (C) Splenic cDCs from IFN-β-/- and IFNAR-/- mice form lower levels of MHC 
I/SIINFEKL complexes. (C) cDCs were stained with 25-D1.16 antibody, MFI was measured by flow 
cytometry, graphs show values for 100ng/ml of SIINFEKL peptide, cells were gated on CD8α+DCs and 
CD8α-DCs. Results are representative of at least three mice for WT, IFN-β-/- and IFNAR-/- in three 
independent experiments. Statistical significance was determined using the paired Student’s t test. 
* P<0.05; *** P<0.005 
 
3.7 Deficiencies in the IFNs system leads to decreased expression of Hsp70 in splenic 
cDCs 
To understand the molecular basis for the decreased formation of MHC/peptide 
complexes, splenic DCs RNA from WT, IFN-β-/- and IFNAR-/- mice was analyzed by 
microarrays for expression of genes known to be involved in antigen processing and 
presentation, co-stimulation or IFNs response. Extensive analysis of the microarrays 
indicated that most of these genes were unaltered in cDCs from the knockout mice. 
The only dramatic difference found was in the expression of the heat shock protein 
Hsp70.1 and Hsp70.3 genes. The expression of these two genes was significantly 
lower in cDCs from IFN-β-/- (approximately 15-20 fold down-regulated in comparison 
to WT) and IFNAR-/- (approximately 75-150 fold down-regulated in comparison to 
WT) mice (Fig. 3.9A).  
To verify the above findings, I first stained for intracellular Hsp70 protein. As shown 
in Fig. 3.10 levels of Hsp70 were indeed lower in IFN-β-/- and IFNAR-/- cDCs 
compared to WT cDCs. Most likely due to presence of other highly homologous 
members of the Hsp70 family and the low sensitivity of the antibody, differences were 
not very pronounced.  
C 
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However, in confirmation of the microarray data, transcriptional levels of Hsp70.1 
were severely decreased in DCs from IFN-β-/- and IFNAR-/- mice in comparison to WT 
(Fig. 3.9B). Moreover, treatment with low amounts of rIFN-β (0.1U/ml) increased 
Hsp70 levels in both WT and IFN-β-/- DCs, whereas treatment with 5U/ml of rIFN-β 
did not markedly change the Hsp70 levels (Fig. 3.9C). This correlates well with the 
functional restoration of IFN-β-/- cDCs at low, but not at high concentrations of rIFN-
β. Consistent with this finding, 24h of poly I·C administration up-regulated Hsp70.1 
levels in WT as well as in IFN-β-/- cDCs (Fig. 3.9D). 
 
 
Figure 3.9 Microarray analysis of splenic cDCs from WT, IFN-β-/- and IFNAR-/- mice showed 
down-regulation of heat shock protein 70.1 and 70.3 (Hsp70.1 and Hsp70.3) in knockout mice. (A) 
Affymetrix gene array analysis of splenic cDCs. RNA was prepared from sorted splenic CD8α+DCs and 
CD8α-DCs from WT, IFN-β-/- and IFNAR-/- mice. All samples were repeated twice with individually 
sorted cells and averaged. (B) Quantitative real-time PCR (qRT-PCR) of RNA from splenic cDCs 
sorted from WT, IFN-β-/- and IFNAR-/- mice. (C) qRT-PCR of RNA from splenic cDCs untreated and in 
vitro treated with 0.1U/ml and 5U/ml of murine recombinant IFN-β for 3h. (D) qRT-PCR of RNA from 
splenic cDCs 24h after administration of  poly I·C. Results are representative of at least three from WT, 
IFN-β-/- and IFNAR-/- mice in three independent experiments. 
B 
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3.8 Inhibition of Hsp70 by 15-deoxyspergualin leads to impairment of antigen 
presentation 
To test for a possible causative link between Hsp70 expression and antigen 
presentation, I used 15-deoxyspergualin (DSG), a pharmacological inhibitor of Hsp70. 
DSG is a synthetic derivative of spergualin from Bacillus laterosporus and binds to  
 
 
Figure 3.10 Lower amounts of Hsp70 protein in IFN-β and IFNAR deficient cDCs in comparison 
to WT cDCs. Intracellular staining of Hsp70 protein in sorted splenic cDCs from WT, IFN-β-/- and 
IFNAR-/- mice. Results are representative of at least three mice per group in three independent 
experiments. FMO (fluorescence minus one) control. Values represent MFI for indicated group. 
 
Hsp70 and Hsp90 (105, 133, 134). Therefore, I treated mice for 6 days with DSG and 
then tested the splenic cDCs of such mice for Hsp70 expression. Intracellular staining 
revealed that DSG treatment led to partial reduction of Hsp70 level in WT cDCs (Fig. 
3.11A). In contrast, expression of surface molecules involved in T cell stimulation was 
not affected by this treatment (Fig. 3.12). 
Then I tested cDCs isolated from DSG treated mice for their capacity to stimulate 
CD4+ and CD8+ T cells. Clearly, cDCs from DSG treated mice exhibited a reduced 
ability to stimulate OT I or OT II T cells compared to cDCs from untreated mice, 
independent of whether protein or peptides were used as antigen (Fig. 3.11B). This 
was consistent with the claims that DSG abrogates the ability to present antigen in the 
context of both MHC I and MHC II (105, 133-135).  
In addition, compared to untreated control, cDCs from DSG treated mice revealed 
lower surface levels of MHC/peptide complexes (Fig. 3.11C) suggesting that Hsp70 is 
necessary for efficient formation of MHC/peptide complexes. Thus, by supporting the 
expression of Hsp70, constitutive IFN-β expression in vivo helps to maintain cDCs in 
a primed and competent state for antigen presentation.  
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Figure 3.11 In vivo inhibition of Hsp70 by 15-deoxyspergualin leads to impaired antigen 
presentation by splenic cDCs. (A) Intracellular staining of Hsp70 in splenic cDC from mice untreated 
and treated with 15-deoxyspergualin. (B) Antigen presentation assay with splenic cDCs from untreated 
mice and mice treated with 15-deoxyspergualin. Splenic cDCs were incubated with purified, CFSE 
labeled OT I or OTII cells for 1.5 days (class I restricted peptide) and 2.5 days. OVA257-264 peptide 
concentration 10ng/ml, OVA323-339 2µg/ml, OVA protein 1mg/ml (class II presentation) or 500µg/ml 
(class I presentation). The proliferative response of T cells was enumerated by flow cytometry. Data are 
representative of at least five mice for WT untreated and DSG treated in three independent experiments. 
(C) DCs from untreated and DSG treated mice were loaded for 1h with 100ng/ml of SIINFEKL peptide, 
washed and stained with 25-D1.16 antibody recognizing MHC I/SIINFEKL peptide complexes. Graph 
shows MFI values for five mice per group. Data are representative of two independent experiments. 
Statistical significance was determined using the paired Student’s t test. * P<0.05; **   P<0.01; 
*** P<0.005 
 
 
3.9 Splenic dendritic cells from Hsp70.1/3-/- mice are impaired in T cell stimulation 
In order to explicitly demonstrate the involvement of the Hsp70.1 and Hsp70.3 
proteins in antigen presentation and thus confirm that in the absence of IFN-β or IFNs 
signaling down-regulation of Hsp70 result in impaired antigen presentation I utilized 
Hsp70.1/3 double knockout mice (122). The surface phenotype of cDCs from      
Hsp70.1/3 -/- mice appeared to be very similar to the surface phenotype of cDCs from 
WT (data not shown). 
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Figure 3.12 Unaltered surface phenotype of splenic cDCs after DSG treatment. Splenocytes 
isolated from C57BL/6 WT mice were untreated or treated for 6 days with 10mg/kg of DSG and stained 
for indicated surface markers. Graphs show MFI values of expression of appropriate marker. MFI was 
measured for at least five mice per group. Data are representative of three independent experiments. 
 
To test the antigen presentation capacity of Hsp70.1/3 -/- cDCs, cells were sorted and 
loaded with appropriate OVA peptides or whole protein and incubated with OT I or 
OT II transgenic T cells. The results clearly show that cDCs from Hsp70.1/3-/- are 
impaired in their ability to present OVA derived peptides as well as whole protein to 
naive T cells when compared to WT cDCs (Fig. 3.13). This further substantiates my 
finding that down-regulation of Hsp70 in the absence of IFN-β or IFNs can alter 
antigen presentation. The discovery that IFNs signaling regulates MHC/peptide 
complex formation by Hsp70 proteins highlights a hitherto unrecognized mechanism 
via which IFNs might regulate presentation of self antigens in the steady state and has, 
therefore, important consequences for our understanding of how regular homeostatic 
conditions are maintained in the immune system. 
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Figure 3.13 Knockout of Hsp70.1 and Hsp70.3 leads to impaired antigen presentation by splenic 
cDCs. Antigen presentation assay with splenic cDCs sorted from Hsp70.1/3-/- and WT mice. Cells were 
loaded with appropriate OVA derived peptides or whole OVA, washed and incubated in vitro with 
CFSE labeled OT I or OTII cells for 1.5 days (class I restricted peptide) and 2.5 days. OVA323-339 
peptide concentration 2µg/ml, OVA protein 1mg/ml (bottom panel, MHC II presentation). The 
proliferative response of T cells was enumerated by flow cytometry. Data are representative of three 
mice for Hsp70.1/3-/- and WT in two independent experiments. Statistical significance was determined 
using the paired Student’s t test. * P<0.05; **   P<0.01; *** P<0.005 
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 INFLUENCE OF B CELLS AND IMMUNOGLOBULINS ON THE ANTIGEN 
PRESENTATION CAPACITY OF SPLENIC DENDRITIC CELLS 
 
The function of T and B cells is strongly influenced by DCs. For instance, it is well 
established that DCs and T cells have to interact to initiate adaptive immune 
responses. In addition, B cells need T cell help to start their major function to produce 
antibodies, but direct presentation of antigen to B cells has also been demonstrated 
(136). On the other hand activated T cells provide feedback signals to DCs and induce 
their maturation. Under these circumstances, DCs lose their adhesive and phagocytic 
capacities via mechanism called “T cell-mediated terminal maturation” (137). This 
maturation is initiated by cytokines produced by T cells as well as by direct cell-cell 
interactions, that include CD40/CD40L pathway.   
B cells also exhibit profound regulatory effects on the function of DCs. For example, 
in the absence of B cells DCs have an impaired capacity to induce differentiation of 
IL-4 producing T cells (138, 139). 
The goal of this part of the thesis was to characterize DCs from mice that lack T and B 
cells, like RAG (recombination activated gene) deficient mice, and to evaluate the 
influence of mature B and T cells on the antigen presenting ability of splenic cDCs. 
The results demonstrated, that cDCs from RAG-/- mice were impaired in their ability to 
present soluble antigen. I could show that this was due to their highly aggressive 
protein degradation compartments. In contrast, cDCs from RAG-/- mice were very 
efficient in presenting cell associated antigens, like antigen associated with apoptotic 
cells. This might be explained by the fact, that RAG-/- cDCs express high levels of C1q 
complement members, which are responsible for the clearance of apoptotic cells. 
Finally, I showed that cDCs from RAG-/- mice express increased levels of Fcγ 
receptors (FcγR). Consequently, administration of B cells or soluble immunoglobulins 
into RAG-/- mice recovered the impaired presentation capacity of splenic cDCs for 
soluble antigen. Taken together, I could show here that the cellular composition of the 
spleen and antibodies in the blood dramatically influence the character and function of 
cDCs. 
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4.1 Splenic cDCs from RAG deficient mice exhibit similar surface phenotype to 
WT cDCs 
Products of the RAG-1 and RAG-2 genes are responsible for initiation of a complex 
series of DNA rearrangements collectively called variable-diversity-joining (V(D)J) 
recombination. This process is responsible for the diverse repertoire of antigen 
receptors present on B and T cells (140). Deletion of such genes leads to an arrest of B 
and T cells differentiation at an early stage. In consequence, RAG deficient animals 
lack mature B and T lymphocytes (120, 121). 
It was shown in several studies that arrival, localization and persistence of DCs in the 
spleen of RAG-/- mice are not particularly altered in comparison to WT mice (120, 
141, 142).  However, the numbers of non-erythroid cells in the spleen of RAG-/- mice 
is between five to nine times lower than numbers in the spleen of corresponding WT 
littermates (120, 141). The percentage of RAG-/- splenic cDCs is similar to the 
percentage of cDCs found  in WT mice (Fig. 4.1A) (141, 142).  
To investigate whether the absence of lymphocytes in the spleen of RAG-/- mice 
influences the resident cDCs, I first analyzed cDCs for different cell surface markers 
and co-stimulatory molecules. Comparable expression patterns in both WT and RAG-/- 
mice were revealed (Fig. 4.1B). Interestingly, I observed significant differences in the 
expression levels of MHC I and MHC II molecules. Such molecules were expressed at 
higher levels in RAG-/- cDCs. Although this might suggest different maturation status 
of RAG-/- and WT cDCs, the grossly equal levels of co-stimulatory molecules on cDCs 
in both mice argued to the contrary (Fig. 4.1B). In addition under inflammatory 
conditions, that normally result in full maturation of DCs the increase of expression of 
MHC molecules would be much more pronounced. Therefore, the maturation status of 
splenic cDCs from RAG-/- and WT mice may be considered similar. 
 
4.2 Splenic cDCs from RAG-/- mice are impaired in presentation of soluble antigen 
Since the major function of DCs is the presentation of antigen and activation of 
T cells, I decided to examine splenic cDCs from RAG-/- and WT mice in antigen 
presentation assay. First, I resorted to soluble OVA as a model antigen and OT I 
transgenic T cells as responder cells. Data depicted on Fig. 4.2 show that cDCs sorted 
from RAG deficient mice were highly impaired in cross-presentation of the intact  
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Figure 4.1 Similar percentage and surface phenotype of RAG-/- and WT splenic cDCs. (A) 
Splenocytes were isolated from WT and RAG deficient mice and stained with appropriate mAbs. Dot 
plots show similar percentage of CD11chi cDCs population in spleens of both mice. Two subpopulations 
of splenic cDCs were also similar in respect to their percentage in WT and RAG-/- mice. (B) 
Splenocytes of WT and RAG-/- mice were isolated, stained for indicated surface markers and analyzed 
by flow cytometry. Graphs show mean fluorescence intensity (MFI) values of each marker. Data are 
representative of at least 4-5 mice per group in six independent experiments. Statistical significance was 
determined using the paired Student’s t test. * P<0.05; ** P<0.01; *** P<0.005, ns – not significant  
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OVA protein and to some extend even in presentation of “pre-processed” peptide 
(OVA257-264). 
Such properties of RAG-/- DCs were already described before (143), although in a 
different experimental model. My data substantiated that this might be a general 
characteristic of cDCs from RAG deficient mice. 
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Figure 4.2 RAG-/- DCs are impaired in presentation of soluble OVA to OT I cells.  Purified OT I 
transgenic T cells were labeled with CFSE and incubated for 1.5 days (peptide) or 2 days (OVA) with 
splenic cDCs (CD11chi, CD11b+/-, CD8α+/-, B220-) in ratio 10:1. First cDCs from WT and  RAG-/- mice 
were loaded with OVA257-264 peptide or whole OVA protein for 1h and further were washed intensively. 
The proliferative response of T cells was enumerated by flow cytometry. Data are representative of five 
independent experiments.  
 
4.3 Transcriptional profile of cDCs from RAG deficient and WT mice 
 
To investigate the molecular mechanism that could explain above observations, I 
decided to examine the transcriptional program of splenic cDCs from RAG-/- mice in 
comparison to cDCs from WT mice. Splenic cDCs from RAG-/- and WT mice were 
sorted and prepared RNA was analyzed by microarrays. I could distinguish three 
group of genes, which were differentially regulated between RAG-/- and WT cDCs: 
endosomal and lysosomal enzymes (endo-lysosomal enzymes), members of the C1q 
complement component and particular surface receptors and molecules (Fig. 4.3A- C).  
The level of up-regulation of genes in RAG-/- cDCs for endo-lysosomal enzymes 
varied between 45 and 10 times, for C1q complement component between 55 and 25 
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times and for surface receptors and molecules between 68 and 26 times. These three 
panels of genes should shed a new light on the character of RAG-/- cDCs and provide 
possible explanations for their impaired antigen presentation abilities.  
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Figure 4.3 Transcriptional profile of RAG-/- cDCs show up-regulation of lysosomal and endosomal 
enzymes, C1q complement members, particular surface receptors and molecules in comparison to 
WT cDCs. (A-C) Affymetrix gene array analysis of splenic cDCs. mRNA was prepared from sorted 
splenic CD8α+DCs and CD8α- DCs from WT and RAG-/- mice. All samples were repeated twice with 
individually sorted cells and averaged. 
 
The up-regulation of endo-lysosomal enzymes, which are responsible for antigen 
degradation, may suggest that RAG deficient cDCs exhibit more aggressive 
degradation properties. Once antigen is degraded excessively, APCs can no longer 
efficiently present it to T cells. This is reminiscent of the far more aggressive 
degradation of antigen by macrophages (Mφ) compared to DCs (144). On the other 
hand the  up-regulated mannose receptor and other C-type lectin receptors, like SIGN-
R1 and SIGN-R2 found in RAG-/- cDCs suggested a highly efficient up-take of soluble 
antigen and its deviation into the cross-presentation pathway (145). Nevertheless, even 
under these conditions high amounts of endo-lysosomal enzymes may degrade the 
antigen too fast to be loaded onto MHC I molecules and thus abrogating cross-
presentation. 
Beyond very well established role in initiation of the “classical pathway” of 
complement activation, members of C1q complement family are potent regulators of 
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DCs differentiation, activation and antigen presentation (146). They can opsonize 
apoptotic cells for DC phagocytosis and enhance the uptake of apoptotic cells without 
influence on surface expression of CD40 and CD86. Moreover, C1q was shown to 
have tolerogenic properties, since C1q deficient animals develop autoimmunity (146). 
This might also be connected with their inability to take up apoptotic cells.  Since 
RAG-/- cDCs express higher levels of C1q complement members, they may be 
specialized in the presentation of particular antigens, like cell associated antigens as 
found in apoptotic cells. 
Cell surface receptors for immunoglobulins (FcγR) are now well characterized and 
have been shown to play an important role in the immune system. They represent a 
paradigm for the balance of positive and negative signals, since they are generally 
present as receptor pairs that consist of activating and inhibitory molecules. FcγR are 
also well known for their role in setting the threshold for B cell activation. Moreover 
they were shown to regulate the maturation of DCs. Especially FcγRIIB was proposed 
to prevent spontaneous maturation of DCs, thereby promoting steady state tolerance 
(147, 148). Therefore, signaling through these receptors may represent an important 
issue in the regulation of RAG-/- cDCs function. 
In addition to the higher expression of FcγR microarrays showed an up-regulation of 
CD163 (scavenger receptor) and CD14 (co-receptor for TLR4 and TLR2) by RAG 
deficient cDCs. Since all these molecules are known to be especially highly expressed 
by Mφ and monocytes this may suggest that the actual character of RAG-/- derived 
cDCs is similar to Mφ or monocytes. 
 
4.4 Absence of T and B cells leads to enhanced protein degradation by splenic cDCs 
 
The up-regulation of endo-lysosomal enzymes observed by microarrays suggested a 
more aggressive degradation of soluble antigen in RAG deficient cDCs.  To confirm 
this I used two fluorescently labeled OVA proteins, OVA-Cy5 and DQ-OVA. OVA-
Cy5 does not require processing to give fluorescence, therefore signal intensity in Cy5 
channel indicate efficiency of Ag uptake by DCs. Opposite is true for DQ-OVA, it 
requires proteolytic degradation to give fluorescent signal, therefore for DQ-OVA 
signal intensity corresponds with Ag degradation. Indeed, as suggested by the 
expression level of surface receptors RAG-/- cDCs showed a slightly more efficient up-  
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Figure 4.4 RAG deficient cDCs exhibit more aggressive degradation of soluble antigen in 
comparison to WT cDCs. (A) WT and RAG-/- splenic cDCs were sorted and incubated for 1h with 
indicated concentrations of OVA-Cy5 (left panel). WT and RAG-/- splenic cDCs were sorted and 
incubated with 62.5µg/ml of DQ-OVA for indicated time points (right panel). Further cells were 
washed intensively and analyzed by flow cytometry. (B) Sorted WT and RAG-/- cDCs were loaded with 
OVA-bio for 1h, washed intensively, lysed, separated in 10 % SDS-PAGE and transferred to a PVDF 
membrane. Further were incubated with appropriate Abs and developed with advanced ECL. (C) WT 
and RAG-/- were sorted, incubated with appropriate concentrations of OVA peptide SIINFEKL 
(OVA257-264), washed carefully and stained with 25-D1.16 mAb. Number of MHC I/SIINFEKL 
complexes was assessed by flow cytometry. Data are representative of three independent experiments. 
Statistical significance was determined using the paired Student’s t test. * P<0.05; ** P<0.01; 
*** P<0.005 
 
 
take of OVA-Cy5 compared to WT cDCs. In addition, degradation of DQ-OVA was 
far more effective when RAG-/- cDCs were tested (Fig. 4.4A). 
Aggressive degradation of soluble OVA by RAG-/- was confirmed by immunoblot. 
Sorted cDCs from WT and RAG deficient mice were loaded with biotinylated OVA 
(OVA-bio) and examined for the appearance of degradation products. After 1h OVA 
degradation products were clearly detectable in WT cDCs, where in RAG-/- cDCs they 
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were no longer present (Fig. 4.4B). Thus, in the absence of mature T and B 
lymphocytes, cDCs exhibit increased proteolytic activity for soluble proteins. As a 
consequence, lower numbers of MHC I/SIINFEKL peptide complexes are found on 
surface of RAG-/- cDCs compared to WT cDCs (Fig. 4.4C). Thus, despite the slightly 
higher amounts of antigen that is endocytosed by RAG-/- cDCs compared to WT cDCs, 
the rapid degradation hampers efficient antigen presentation. 
 
4.5 Splenic cDCs from lymphopenic hosts can efficiently present cell associated 
antigens 
Inefficient presentation of soluble antigen on the one hand and up-regulation of C1q 
complement components by splenic cDCs on the other hand (Fig. 4.3B and 4.5A) in 
the absence of mature T and B lymphocytes, suggested that such DCs may be prone to 
present peculiar antigens. Since C1q molecules are known to facilitate phagocytosis of 
apoptotic cells, I decided to test RAG-/- and WT cDCs for the presentation of antigens 
associated with apoptotic cells. To test this, I used the EG7-OVA cell line, a derivative 
the thymoma EL-4 transfected with OVA (127). EG7-OVA cells were UV-irradiated 
(9mJ/cm2) to induce apoptosis, and further incubated with RAG-/- and WT cDCs. As 
responder cells OT I T cells were used. Interestingly, under these conditions T cell 
proliferation induced by RAG-/- cDCs was comparable to that induced by WT cDCs 
(Fig. 4.5B). This indicates, that indeed RAG-/- cDCs can efficiently phagocytose and 
present cell associated antigen derived from apoptotic cells.  
Results from this experiment prompted me to investigate the overall content of 
apoptotic leukocytes in the spleen of RAG deficient mice. I performed staining using 
annexin V, which binds to the phosphoserine exposed on the cell surface at the early 
stage of apoptosis. Indeed, spleens of RAG-/- mice contained significantly more 
apoptotic cells than spleens of WT mice (Fig. 4.5C). This may explain why cDCs from 
RAG-/- mice are very efficient in presentation of cell associated antigens. Obviously, in 
their neighborhood an accumulation of apoptotic debris is found. Impaired clearance 
of apoptotic cells would lead to the pathological accumulation of necrotic corpses and 
in consequence to inflammation (149). Hence, an efficient phagocytosis of such debris 
is required to avoid an inflammatory response. Therefore, production of C1q 
complement components by cDCs may be initiated as mechanism to enhance the 
acquisition of apoptotic cells. These proteins were shown to opsonize apoptotic cells 
for DCs phagocytosis. Therefore, higher expression of C1q complement members in 
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RAG-/- cDCs as compared to WT may represent an adaptation for clearance of 
apoptotic cells present in the spleen. 
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Figure 4.5 RAG-/- cDCs are specialized in presentation of cell associated antigens. (A) Quantitative 
real-time PCR (qRT-PCR) of RNA from splenic cDCs sorted from WT and RAG-/- mice for C1qa (left 
panel) and C1qb (right panel). (B) The purified OT I transgenic T cells were labeled with CFSE and 
incubated for 2 days with splenic cDCs (CD11chigh, CD11b+/-, CD8α+/-, B220-) in ratio 10:1. cDCs from 
WT and RAG-/- mice were preloaded with UV-irradiated EG7-OVA cells for 1h. The proliferative 
response of T cells was enumerated by flow cytometry. (C) Splenocytes of WT and RAG deficient mice 
were isolated and stained with annexin V. Data were analyzed by flow cytometry. All data are 
representative of three independent experiments.  
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4.6 Impaired function of RAG deficient cDCs to present soluble antigen can be 
rescue by B cells 
Next, I wanted to investigate whether the impaired capacity of cDCs from RAG-/- mice 
to present soluble antigen could be recovered. B cells were previously shown to 
regulate the function of DCs. For instance, immune responses to antigenic challenge 
differ in WT and B cell deficient mice (µMT). Although priming of T cells was not 
significantly different, the cytokine profile was clearly distinct (138). Unfortunately, 
this study did not particularly address antigen presentation by splenic cDCs. Another 
study (143) showed, that T cells are necessary for functional maturation of skin 
derived RAG-/- DCs, and that reconstitution of RAG deficient mice with T cells 
rescued ability of skin DCs to present soluble antigen. Despite of the latter data, I first 
addressed the question whether reconstitution of RAG deficient mice with B cells 
alone could recover the function of splenic cDCs. 
To test this WT and RAG-/- mice were i.v. injected with bulk WT CD19+ splenic B 
cells and after 3 weeks cDCs were sorted and their ability to cross-present soluble 
OVA to OT I T cells was tested. Isolated B cells were sufficient to restore the 
impaired function of RAG-/- cDCs (Fig. 4.6). Cross-presentation of soluble OVA by B 
cell reconstituted RAG-/- cDCs was as efficient as by WT cDCs. Therefore, B cells 
alone are sufficient to restore diminished ability to cross-present soluble antigen by 
RAG deficient splenic cDCs. Thus far, the impact of T cells could not be tested for 
reasons of time constrains. Therefore, a similar effect of T cells cannot be excluded. 
 
4.7 Serum and soluble immunoglobulins can recover impaired function of cDCs from 
RAG deficient mice 
The major function of B cells is to produce immunoglobulins. However, B cells might 
also be a source of cytokines. Microarray analysis had revealed the up-regulation of 
FcγR in RAG-/- cDCs. Therefore, binding of immunoglobulins to FcγR might most 
likely modify the function of DCs. In addition, it had been proposed before that 
engagement of FcγR on DCs triggers their maturation and induces efficient antigen 
presentation via both MHC I and MHC II (147).  
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Figure 4.6 Reconstitution of RAG deficient mice with WT B cells leads to restoration of impaired 
function of RAG-/- cDCs. WT and RAG deficient mice were i.v. injected with sorted WT CD19+ B 
cells or PBS. After 21 days mice were sacrificed, splenic cDCs were isolated and tested for their ability 
to cross-present soluble OVA to OT I cells. At least 5 mice per group were used. Statistical significance 
was determined using the paired Student’s t test. * P<0.05; ** P<0.01; *** P<0.005 
 
Particularly FcγRIIB was proposed to prevent spontaneous maturation of DCs in 
steady state (148).  
Therefore, I reconstituted RAG deficient mice with serum from WT mice. Data 
depicted on Fig. 4.7A show, that this treatment completely recovered the impaired 
ability of RAG-/- cDCs to present soluble OVA. This was consistent with the 
possibility that immunoglobulins are required for proper function of cDCs. Serum 
from RAG deficient mice did not recover this function excluding a contribution of 
activated complement or fibrinogen components. 
To compellingly show the contribution of immunoglobulins to cDC maturation I 
administrated purified IgG and IgM to RAG-/- mice. This experiment confirmed that 
the serum effect was due to immunoglobulins. DCs from IgG or IgM injected RAG-/- 
mice were as efficient in cross presentation of soluble OVA to OT I cells as WT cDCs 
(Fig. 4.7B). Therefore, in extension to published data (143) I could show, that soluble 
immunolglobulins alone are sufficient to recover the impaired antigen presentation 
capacity of cDCs isolated from RAG deficient mice. 
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Figure 4.7 Reconstitution of RAG deficient mice with soluble immunolglobulins recovered 
function of cDCs to cross-present soluble OVA. (A) WT and RAG-/- recipient mice were i.v. injected 
on day 0 and day 7 with 50µl of donor serum. After 14 days splenic cDCs were isolated from recipient 
mice and tested in antigen presentation assay. (B) WT and RAG-/- recipient mice were i.v. injected on 
day 0 and day 7 with 75µg/ml of IgG, IgM alone or together. After 21 days splenic cDCs were isolated 
from recipient mice and tested in antigen presentation assay. Data are representative of two independent 
experiments. Statistical significance was determined using the paired Student’s t test. * P<0.05; 
** P<0.01; *** P<0.005 
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DIFFERENTIATION OF NKT CELLS INDUCED BY MARGINAL ZONE B CELLS 
COMPARED TO CONVENTIONAL SPLENIC DENDRITIC CELLS 
 
The marginal zone (MZ) of the spleen is a unique structure, found only in this organ. 
The localization and architecture of MZ favors contact with blood borne antigens and 
pathogens. It is characterized by a peculiar composition of leukocytes and 
lymphocytes. Besides macrophages and cDCs, NKT cells are found here. In addition, 
marginal zone (MZ) B cells home to this structure. MZ B cells are claimed to be 
maintained in a pre-activated state. This allows them to respond rapidly to pathogens 
by antibody production (62-64). 
Importantly, amongst all murine APCs, MZ B cells were found to express the highest 
levels of CD1d, the non-classical MHC I molecule that is responsible for presentation 
of lipid and glycolipid antigens. CD1d/lipid complexes are recognized by NKT cells 
that are known to rapidly secrete cytokines such as IL-4 and IFN-γ. This suggests a 
decisive regulatory function during the initial phase of an immune response. Due to 
the high levels of CD1d and the co-localization of both cell types, I postulated that MZ 
B cells may be efficient activators of NKT cells. 
Therefore, I used MZ B cells and splenic cDCs sensitized with α-galactosylceramide 
as APCs for NKT cells stimulation. Both MZ B cells and cDCs proved to be highly 
efficient in priming of NKT cells and to induce their robust proliferation in vitro. 
Interestingly, MZ B cells exclusively induced production of IL-4 by NKT cells 
whereas cDCs induced robust production of IFN-.  
In addition, I could demonstrate that proliferation of NKT cells and IL-4 production 
activated by MZ B cells was dependent on ICOS/ICOSL interactions. Taken together, 
these data suggest that both MZ B cells as well as cDC act as professional APCs for 
NKT cells. Notably, the nature of APC appears to be critical for the polarization of the 
immune response: MZ B-cell-primed NKT cells to induce a cytokine milieu that 
would foster a TH2 response, whereas cDC-primed NKT cells rather favor a TH1 
response.  
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5.1 Marginal zone B cells express high levels of CD1d and co-stimulatory molecules 
To investigate the cell stimulatory capacity of MZ B cells, I first decided to carefully 
characterize the phenotype of MZ B cells in comparison to other splenic B cells, like 
B2 and B1a cells and in addition to splenic cDCs. Fig. 5.1A shows the gating strategy 
for MZ B cells, splenic B cells and cDCs that was used for cell surface analysis as well 
as for later cell sorting.  
MZ B cells are defined as CD19+CD11c-CD23-and CD21/35+ (62-64). For comparison 
CD11chiCD19- cDCs were employed, which are known to be very efficient stimulators 
of T and NKT cells (Fig. 5.1B-C). Results revealed that MZ B cells express very high 
levels of the CD1d molecule. In fact expression was 7 to 8 time higher compared to 
cDCs. This feature of MZ B cells had been observed before (150-152).  In contrast, B1 
cells express CD1d only 2-3 times higher compared to cDC while expression of this 
molecule by B2 B cells was comparable to that found on cDCs. The high level of 
CD1d on MZ B cells confirmed their potential importance in activation of NKT cells. 
 
5.2 Marginal zone B cells can efficiently stimulate proliferation of NKT cells in vitro 
To test this, three types of splenic B cells, B1, B2 and MZ B, as well as cDC were 
purified by cell sorting and tested for their ability to present glycolipids (Scheme 5.1). 
They were sensitized with different concentrations of α-galactosylceramide (αGalCer). 
NKT cells (lin-Dx5-NK1.1int) were isolated from the spleen of Vα14 transgenic mice, 
which contain about 3% of such cells. Sensitized APCs were co-cultured at a ratio of 
1:10 with CFSE-labeled NKT cells and proliferation of NKT cells was measured 2.5 
days later by flow cytometry (Fig. 5.2A and B). Interestingly, MZ B cells are very 
potent activators of NKT cell expansion, comparable to cDCs although at the highest 
tested concentration of GalCer, MZ B cells were roughly two times more efficient in 
priming NKT cells compared to cDCs (Fig. 5.2B). Both, MZ B cells and cDCs, when 
sensitized with lower concentrations of GalCer (0.2g/ml) are still able to activate 
NKT cells efficiently. 
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Figure 5.1 Sorting strategy and analysis of cell surface phenotype of different splenic APCs. (A) 
Splenocytes of  WT mice were isolated, stained and sorted according to indicated gates. Cells were 
analyzed for CD11c and CD19 expression, CD19+ CD11c- cells were analyzed for CD21/CD35, CD23 
and CD5. MZ B cells are CD21/35hiCD23-/lo, B1 cells CD21/35loCD23+CD5lo and B2 cells are 
CD21/35loCD23+CD5-. Splenic conventional DCs were CD11chiCD8α+/-. Cell populations were sorted 
with purity of 95% to 99%. (B) Comparison of co-stimulatory markers on MZ B cells and cDCs. MZ B 
cells indicate the highest expression of CD40 and CD1d surface proteins among all APCs found in 
steady state spleen. (C) Expression of DC associated co-stimulatory molecules by B2 and B1 cells. 
Values in dot-plots indicate mean fluorescent intensity (MFI) of analyzed markers. Representative 
staining for five independent experiments are shown. 
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In contrast splenic follicular B cells, B2 and B1 were not able to induce NKT cell 
proliferation, albeit levels of CD1d and co-stimulatory molecules were similar. This 
experiment shows that indeed MZ B cells alone are able to induce robust NKT cell 
proliferation in vitro. 
High expression of CD40 molecules on both MZ B cells and cDCs suggested that 
activation of such APCs via CD40-CD40L interaction may significantly increase their 
stimulatory capacity during co-culture with NKT cells. To test whether CD40 
signaling would increase the stimulatory capacity of such APCs, mice were treated 
with an agonistic anti-CD40 antibody for four hours. The same splenic cell 
populations were isolated and tested for stimulation of NKT cells as described before. 
However, stimulation of MZ B and cDCs with anti-CD40 in vivo increased their 
efficiency to prime NKT cell only mariginally (Fig. 5.2C). B1 and B2 cells still 
remained unable to stimulate NKT cell proliferation despite the treatment. Thus, the 
licensing by CD40L, that is observed for other APCs when priming T cells does not 
apply here.  
WT, CD1d-/-, β2m-/- Vα14 tg, WT
sorting of splenic 
cDCs and MZ B 
cells
loading with α-GalCer
sorting of NKT 
cells, staining with 
CFSE
incubation of NKT 
cells with APCs
16 hours, 2.5 days
ELISA
IL-4, IFN-γ
PROLIFERATION OF 
NKT CELLS
Brefeldin A
Intracellular staining
IL-4, IFN-γ
 
Scheme 5.1 Schematic representation of the experimental strategy employed for in vitro NKT cells 
activation and proliferation assays. 
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Figure 5.2 MZ B cells can efficiently present lipids to NKT cells in vitro. (A) Purified APCs were 
loaded with GalCer (1µg/ml), washed and co-cultured with NKT cells for 2.5 days in ratio 1:10. 
Proliferation of NKT cells was determined in CFSE dilution assay. (B) Antigen concentration 
dependence of stimulation of NKT cells. (C) APCs were purified from mice treated with anti-CD40 Ab 
(150µg/mouse), loaded with αGalCer and co-cultured with NKT cells. Conditions of the test were like 
in A Data are representative of three independent experiments. 
 
5.3 NKT cells produce IL-4 upon activation by MZ B cells 
NKT cells are known to quickly secrete cytokines upon stimulation and may produce 
cytokines associated either with a TH1 or TH2 immune response. Therefore, their role 
during the immune response might be to drive T cells into a particular direction. The 
APC on which the NKT cells encounter the antigen might be decisive in this reaction. 
Since cDCs and MZ B cells exhibited a similar ability to prime NKT cell proliferation, 
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the question arose whether a similar cytokine profile would be elicited after the 
stimulation by the different APCs. As shown in Fig. 5.3, cDCs primed with GalCer 
are able to efficiently stimulate NKT cells to produce IFN-γ. Intracellular staining 
indicated that around 14% of NKT cells produced IFN-γ after 16h (Fig. 5.3A). The 
percentage of NKT cell producing IFN-γ increased even up to 50% after 2.5 days of 
stimulation (Fig. 5.3B). cDCs were also able to induce production of IL-4. However, 
the percentage of positive cells was clearly lower – around 5% after 16h and 15% after 
2.5 day of co-culture. Most of such NKT cells produced IFN-γ and IL-4 at the same 
time. None of them was triggered to produced IL-17 or IL-10 (data not shown).  
In contrast, MZ B cells loaded with GalCer were not able to induce the substantial 
production of IFN-γ by NKT cells, observed for cDC (Fig. 5.3A, B). Only 6.7% and 
4.8% of NKT cells produce IFN-γ after 16 hours or 2.5 days of stimulation, 
respectively. However, MZ B cells appear to be more prone to induce IL-4 in NKT 
cells. After 16 hours of stimulation 3.5% and after 2.5 days 8.3% of NKT cells 
produce IL-4. Double producers were scarce under these conditions. 
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Figure 5.3 NKT cells produce IFN-γ only after stimulation with cDCs. Production of cytokines by 
NKT cells. cDC or MZ B cells were loaded with 1g/ml of GalCer, washed and co-cultured with NKT 
cells in ratio 1:1 for 16h (A) and 2.5 days (B). Next, cells were incubated with Brefeldin A for 4 h, 
fixed, permeabilized and stained intracellularly for IFN-γ and IL-4. Data are representative of four  
independent experiments. 
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This bias became more obvious when supernatants of such cultures were tested by 
ELISA (Fig. 5.4A and B). cDCs upon GalCer sensitization induce massive secretion 
of IFN-γ by NKT cells, while MZ B cells failed to do so (Fig. 5.4A). In contrast, MZ 
B cells sensitized with GalCer efficiently induced IL-4 secretion by NKT cells at 16h 
(Fig. 5.4B). After 2.5 days, both MZ B cells and cDCs loaded with GalCer 
stimulated NKT cells to produce IL-4 to the same extend. None of the other APC 
populations sensitized with GalCer was able to stimulate NKT cells efficiently (Fig. 
5.4 and data not shown).  
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Figure 5.4 Efficient cytokines production by NKT cells requires presentation of glycolipid by 
splenic APCs. Three populations of splenic APCs: B2, MZ B cells and cDCs were purified as 
previously described. Cells were sensitized with 1µg/ml of αGalCer and incubated for 2.5 days with 
CFSE labeled NKT cells in ratio 1:2. After 16 and 2.5 days incubation of APCs with NKT cells, 
supernatants were collected and concentration of  (A) IFN-γ and (B) IL-4 was determined in ELISA. 
Data are representative of three independent experiments. 
 
5.4 Proliferation of NKT cells is CD1d dependent 
In contrast to conventional αβ T cells, NKT cells can proliferate without stimulation 
via the TCR. For instance, cDCs stimulated by TLRs agonists can produce cytokines, 
mainly IL-12 and IL-18, which in turn are able to stimulate NKT cells to proliferate as 
2.5 days 
2.5 days 
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well as to produce cytokines. To test whether proliferation of NKT cells and synthesis 
of IFN-γ or IL-4 observed here depends on CD1d/TCR interaction or is driven by the 
IL-12, the following experiment was performed. cDCs and MZ B cells were sorted 
from the spleens of WT and CD1d-/- or β2m
-/-
 mice, which are unable to express CD1d 
molecules. Purified APCs were sensitized αGalCer and co-cultured with CFSE labeled 
NKT cells at a ratio of 1:2. In addition, to test whether IL-12 is involved in NKT cell 
proliferation and cytokine production, anti-IL-12 blocking Ab was added to some 
cultures. Proliferation was measured 2.5 days later (Fig. 5.5A).  
When cDCs of CD1d-/- or β2m
-/- mice were used activation of NKT cells depends on 
secreted cytokines only. In this case NKT, cell proliferation was completely blocked 
by addition of anti-IL-12 Ab. By extrapolation, also under normal conditions 
proliferation of NKT cells induced by cDC might be partially dependent on IL-12 
(Fig. 5.5A). 
In contrast to cDCs, proliferation of NKT cells driven by MZ B cells appeared to be 
completely CD1d dependent. NKT cell primed by MZ B from knockout mice almost 
completely failed to proliferate. Since the MZ B cells cannot produce IL-12, addition 
of anti-IL-12 did not change these results as expected (Fig. 5.5A). 
Analysis of cytokine production (Fig. 5.5B-C) led to several conclusions. After 
sensitization of cDCs by αGalCer, CD1d signaling is irreplaceable and leads to strong 
reduction of IFN-γ production. Blocking of IL-12 has strong impact on cytokine 
production by NKT cells. Absence of both CD1d and IL-12 leads to complete 
abrogation of IFN-γ synthesis. In contrast, MZ B cells can induce IL-4 production in 
NKT cells even in the absence of CD1d, although this is diminished (Fig. 5.5C). 
 
5.5 Marginal zone B cells express higher levels of GITRL and ICOSL compared to 
cDCs 
It was important to find the surface molecules that are responsible for an interaction 
between NKT cells and MZ B cells and their unique stimulatory capacity.  
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Figure 5.5 Proliferation of NKT cells is CD1d dependent. MZ B cells and cDCs were isolated from 
WT and CD1d-/- or β2m
-/- (KO). Cells were loaded with 1µg/ml of αGalCer and incubated for 2.5 days 
with CFSE labeled NKT cells in ratio 1:2. (A) Number of divided (CFSElo) NKT cells was determined 
in FACS. (B-C) MZ B cells and cDCs form WT and CD1d-/- or β2m
-/- mice were prepared as in A. After 
16 and 72h hours of incubation with NKT cells, supernatants were collected and concentration of (B) 
IFN-γ and (C) IL-4 was determined in ELISA. Data are representative of three independent 
experiments.  
 
I first decided to analyze the expression levels of ligands and their receptors, which are 
known to be involved in interplay between conventional APCs and NKT cells. Hence, 
I compared MZ B cells and cDCs for the expression of OX40L, CD27, GITRL and 
ICOSL (153-156). This analysis revealed that two ligands – GITRL and ICOSL were 
expressed significantly higher on the surface of MZ B cells in comparison to cDCs 
2.5 days 
2.5 days 
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(Fig. 5.6). GITR has been previously shown to be essential for activation of NKT cells 
(156), while ICOSL can stimulate CD4+ T cells to secrete IL-4 rather than IFN-γ (155, 
157).Therefore they represent potential candidates, specific for MZ B cells to 
stimulate expansion of NKT cells and their early IL-4 production. 
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Figure 5.6 MZ B cell express higher surface levels of GITRL and ICOSL in comparison to cDCs. 
Splenic cDCs and MZ B cells were isolated and stained for GITRL and ICOSL with appropriate mAbs. 
Graphs show mean fluorescence intensity values (MFI) for indicated molecules. Picture is 
representative of three independent experiments. 
 
5.6 Marginal zone B cells involve ICOS/ICOSL interactions to induce NKT cells 
proliferation and IL-4 production 
To examine whether GITRL, ICOSL or both are involved in activation and 
differentiation of NKT cells when MZ B cells or cDCs were used as APCs blocking 
antibodies were employed. Data presented on Fig. 5.7A, and B shows, that 
proliferation of NKT cells and IL-4 production was not inhibited when a blocking 
anti-GITR antibody was added for both MZ B cells and cDCs. However, when cDCs 
were examined for their capacity to induce IFN-γ in NKT cells, anti-GITR Ab strongly 
diminished the response (Fig. 5.7C). Thus, MZ B cells do not use GITR/GITRL 
interaction to drive NKT cells expansion and IL-4 production while, cDCs require this 
interaction to stimulate IFN-γ production.  
Then the second candidate, ICOSL was examined. Interestingly, in this case I found 
that proliferation of NKT cells, was highly impaired when they were stimulated by 
MZ B cells in presence of anti-ICOSL Ab (Fig. 5.7D). Similarly, IL-4 production by 
RESULTS PART III 
109 
 
NKT cells activated by MZ B cells was almost completely blocked (Fig. 5.7E). In 
contrast, IFN-γ production triggered by cDCs was not affected by this Ab (Fig. 5.7F). 
Thus, the dichotomy observed for cytokine production is reflected by a dichotomy of 
the co-stimulatory molecule involved in triggering the NKT cell response. 
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Figure 5.7 MZ B cells require ICOS/ICOSL interaction to stimulate NKT cells proliferation and 
IL-4 production. (A-C) MZ B cells do not involve GITR/GITRL interaction to stimulate NKT cell 
proliferation and IL-4 production but this interaction is required for IFN-γ production when cDCs are 
used as APCs. MZ B cells and cDCs were isolated and sorted as before, further were loaded with    
αGalCer (1µg/ml) and incubated with sorted NKT cells in ratio 1:1 for 2.5 days in the presence of 
blocking anti-GITR Ab. (D-F) MZ B cells require ICOS/ICOSL interaction to stimulate NKT cell 
proliferation and IL-4 production. Assay conditions as described above, cells were incubated in the 
presence of blocking anti-ICOSL Ab. Data are representative of three independent experiments.  
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5.7 Marginal zone B cells can efficiently present lipids to NKT cells in vivo 
The final important question was, whether the cellular interactions demonstrated 
above have some in vivo relevance. To demonstrate this, sorted MZ B cells and cDCs 
from spleens of WT mice were loaded ex vivo with αGalCer to be tested in vivo for 
their NKT cell stimulatory capacity. However, MZ B cells are known to be able to 
transfer antigen to other immune cells, like DCs (66). Therefore, such sensitized APCs 
were transferred into CD1d deficient mice. The APCs of CD1d deficient mice are not 
able to present lipid antigens by themselves. Unfortunately, NKT cells cannot develop 
in the absence of CD1d. To compensate this defect, 2h before the assay an APC-free 
population of NKT cells was injected i.v. into the recipient mice. Subsequently, the 
sorted, antigen loaded APCs were administered. After 16h, spleens of recipient mice 
were removed, and splenocytes were analyzed for intracellular IL-4 and IFN-γ 
(Scheme 5.2).  
Results from this experiment confirmed that MZ B cells alone are indeed very potent 
stimulators of NKT cells. In addition, they are able to induce production of IL-4 
exclusively (1.6% positive cells) (Fig. 5.8). I could confirm, that cDC can induce a 
robust production of IFN-γ (11.3% positive cells) and only a moderate production of 
IL-4 by NKT cells (2.5% of positive cells). This experiment clearly shows that the 
different stimulatory capacity of MZ B cells and cDC are not limited to in vitro 
conditions. Also in vivo, MZ B cells appear as APCs that stimulate NKT to secrete 
moderate amounts of IL-4 and in consequence provide a cytokine milieu that favors 
TH2 responses. In contrast, cDCs are very potent NKT cell activators. Upon such 
stimulation, NKT cells secrete mostly IFN-γ, and therefore promote a TH1 immune 
response. 
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Scheme 5.2 In vivo NKT cells activation by sensitized MZ B cells or cDCs. 
 
IFN-
IL
-4
MZ B cells                  cDC 
0.1                         0.0          0.0                         0.0
0.0                                        0.5
1.6                          0.1         0.9                        1.6
0.1                                       9.3
APC
- αGalCer
APC
+ αGalCer
 
Figure 5.8 MZ B cells can efficiently present lipids to NKT cells in vivo. MZ B cells and cDCs were 
sorted from spleens of WT mice, ex vivo loaded with αGalCer (2µg/ml), washed and i.v. injected into 
CD1d-/- recipients. Before NKT cells were injected into recipient mice. After 16h spleens of CD1d-/- 
mice were removed, splenocytes were isolated and incubated for 4h with Brefeldin A. After stimulation 
cells were intracellularly stained for IL-4 and IFN-γ. Data are representative of two independent 
experiments. 
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DISCUSSION 
The overall goal of this thesis was to investigate the interaction of antigen presenting 
cells (APCs) with other cells of the immune system since on the one hand, APCs 
shape the immune response and on the other hand immunocytes shape the APCs. 
To address this question, first the influence of IFN-β and its signaling on cell mediated 
immunity was investigated. I could show, that constitutive production of type I IFNs is 
crucial for proper antigen presentation of self antigens in steady state. 
I could also demonstrate how lymphocytes, in particular B cells can shape the 
character and function of cDCs. When splenic cDCs have to differentiate under 
lymphopenic conditions, their character and their ability to present soluble antigen is 
drastically changed. Interestingly, already reconstitution of lymphopenic mice with 
soluble immunoglobulins was able to rescue the ability to present soluble antigen 
despite the absence of mature T and B lymphocytes. 
Special anatomical location and access to antigen may also influence character of 
immune response. Therefore in this context two types of APCs - cDCs and MZ B cells 
were compared. Both are very potent stimulators of NKT cells expansion. 
Nevertheless, the type of immune response they induce is clearly distinct. MZ B cells 
are responsible for early IL-4 production by NKT cells, while cDCs trigger abundant 
IFN-γ production. This observation may critically contribute to the explanation of the 
paradigm of TH1/TH2 regulation. 
 
6.1 Influence of constitutive production of type I IFNs on antigen presentation ability 
of splenic cDCs 
IFNs are found in high amounts in cells exposed to viruses. They were first 
characterized and named as such on the basis of their antiviral activity. It is now well 
known that IFNs have widely overlapping, pleiotropic and immunomodulatory effects 
and their production is not the sole preserve of viral infections but they are also 
induced in response to bacterial and parasitic infections (16, 19, 158). IFNs represent 
important immunomodulators for the innate as well as the adaptive arm of the immune 
system (19, 21). They exert broad regulatory effects and various subtypes of DCs are 
affected by these cytokines (16, 19-21, 158). For instance, IFN-α can promote antigen 
cross-presentation by enhancing endosomal processing, up-regulating the expression 
of co-stimulatory molecules and augmenting dendritic cell viability in settings of viral 
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infection (21, 23, 24, 131, 159, 160). In addition, direct stimulation of T cells by IFN-
α has been shown to be essential for efficient induction of cross-priming (24). 
Furthermore, IFN-α/β were described as crucial survival factors for activated T cells 
(26). Importantly apart from that, even in the absence of infection spontaneous low 
level production of IFN-β has been shown to occur (16). 
The host response elicited by IFNs is largely dependent on signal strength. Most of the 
studies carried out to date have focused on the cellular effects induced by the high 
levels of IFNs elicited under inflammatory conditions. However, whether the low 
levels of IFNs produced under non-inflammatory conditions have an important 
housekeeping immune function is not known. This work shows now that the low but 
constitutive production of IFN-β is necessary for maintaining DCs in a state competent 
for antigen presentation. Compared to those from WT mice, DCs freshly isolated from 
spleens of IFN-β-/- and IFNAR-/- mice were found to be highly impaired in antigen 
presentation to CD4+ and CD8+ T cells. This defect could in part be rectified with 
exogenous rIFN-β or through in vivo induction of IFN-α using synthetic dsRNA. 
Interestingly, restoration of function was possible with extremely low amounts of 
rIFN-β, probably mimicking amounts produced constitutively. Failure of IFN-β-/- DCs 
cultured with high rIFN-β levels to activate T cell proliferation might be attributed to 
negative feedback mechanisms activated by a strong IFN-β signal.  
The function of DCs is not only influenced by cytokines present in their environment, 
but also by other cells of the immune system, particularly T cells. Therefore, splenic 
cDCs isolated from IFN-β deficient mice theoretically could be altered due to an effect 
of IFN-β deficiency on T cells. It was shown before that IFN-α and IFN-β have direct 
effect on activated T cells and prevent their death during inflammatory conditions 
(26). Activated T cells can provide feedback signals to DCs and induce their 
maturation. This can be mediated by cytokines produced by T cells as well as by cell-
cell interactions, including CD40L-CD40 interactions (161). However, this 
phenomenon is unlikely to play a significant role in steady state conditions because of 
the lack of activated T cells. T cell mediated conditioning of DCs via B7-H1 in 
homeostasis has recently been shown to play an important role in inducing DC 
maturation (162). However, as surface expression of B7-H1 was not altered on IFN-β-
/- and IFNAR-/- cDCs in comparison to WT cDCs, one may assume that this is not the 
case in situation here. Moreover, I demonstrated that  rIFN-β treatment in vitro can 
regulate cDCs function and Hsp70 levels. 
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Potential roles of IFNs in antigen presentation have previously been postulated. 
However, as mentioned above such effects have only been observed for high levels of 
IFNs reminiscent of inflammation. For instance, induction of IFNs in DCs by dsRNA 
and LPS in vitro was shown to up-regulate co-stimulatory and MHC molecules hence 
enhancing their ability to activate CD8+ T cells (20). Conversely, results presented 
here show that the antigen presentation defects in splenic IFN-β-/- and   IFNAR-/- DCs 
are neither due to low expression of co-stimulatory and MHC molecules nor a block in 
antigen capture and processing. I demonstrate that the defect is due to a blockade in a 
step downstream of antigen processing: MHC/peptide complex formation. 
Furthermore, the data presented here strongly suggest that impairment in the 
MHC/peptide complex formation step caused by the absence of IFNs signaling is due 
to down-regulation of Hsp70.  
The 70kD Hsps Hsp70.1 and Hsp70.3 belong to a larger, highly homologous and 
conserved gene family whose expression can be significantly induced in response to a 
number of pathophysiological conditions including pathogen exposure (163). In 
addition to a generalized role in protein folding and transport, the proteins also have 
distinct functions in the promotion of antigen processing and presentation (105-108). 
Hsp70 proteins are involved in chaperoning proteins/peptides during degradation and 
during antigen presentation via MHC I as well as via MHC II. Hsp70 has been shown 
to physically associate with the transporter associated with antigen processing (TAP) 
hence enabling efficient loading of chaperoned peptides onto MHC I molecules (105, 
106, 109). In addition, a role for Hsp70 in antigen presentation by MHC II molecules 
has also been described (105, 111). 
By microarray and qRT-PCR analysis, I found that in the absence of a functional IFNs 
system in vivo, the expression of Hsp70.1 and Hsp.70.3 in splenic cDCs was 
significantly down-regulated. In addition, partial blockade of Hsp70 protein in WT 
cDCs using the pharmacological inhibitor DSG resulted in a diminished ability to 
activate T cells. This correlated with a decrease in the surface MHC/peptide 
complexes on WT splenic DCs after treatment with DSG. These results were further 
substantiated when I analyzed the ability of cDCs from Hsp70.1/3-/- mice to present 
soluble OVA to naive CD4+ and CD8+ T cells. The function of such cDCs was highly 
impaired when compared to WT cDCs, suggesting that indeed altered levels of Hsp70 
in IFN-β-/- and IFNAR-/- cDCs are responsible for impaired antigen presentation in the 
steady state. 
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From the data presented here, one could expect that in the absence of chaperones, like 
Hsp70, when formation of antigenic MHC/peptide complexes is impaired, total levels 
of surface MHC molecules should be diminished. Nevertheless, experiments show no 
differences between WT, IFN-β-/- and IFNAR-/- cDCs in total surface MHC I and 
MHC II expression. Likewise, the analysis of the surface phenotype of Hsp70.1/3-/- 
cDCs showed no significant difference in comparison to WT cDCs (data not shown). 
Possibly, Hsp70 might be required for efficient presentation of particular peptides, like 
the ones employed in our study, but not for the others. Therefore, lack of Hsp70 might 
not be reflected by changes of total surface MHC levels. However, the exact molecular 
reason for this phenomenon remains to be elucidated. 
The discovery that basal IFNs production regulates efficiency of MHC/peptide 
complex formation via the expression of Hsp70 is a novel and important finding not 
only in the context of pathogen recognition but also in homeostasis. Not all pathogens 
are associated with robust IFNs production. Therefore by sustaining Hsp70 expression, 
constitutively produced IFNs probably ensure that DCs are kept in a primed state for 
efficient presentation of antigens from such pathogens. An equally or more important 
function could be in the maintenance of tolerance to self antigens. DCs that capture 
and present antigen under non-inflammatory conditions are generally believed to 
acquire tolerogenic properties and generate regulatory T lymphocytes that potentiate 
tolerogenic responses.  
 
6.2 Cellular composition of the spleen imprints the character and function of cDCs 
 
The immune system is a highly dynamic network, where specialized cells interact with 
each other to elicit either protective immune responses or maintain tolerogenic 
conditions. These interactions include cell-cell interactions but also interactions of 
soluble ligands with their cellular receptors, which additionally may be influenced by 
particular anatomical locations. For instance, as I have shown above, the development 
and function of cDCs is critically controlled by soluble molecules, like IFN-β. In the 
second part of my thesis, I addressed the question how the cellular composition of the 
spleen, especially presence of B cells and their products imprints the character and 
antigen presenting capacities of splenic cDCs.  
Impaired function of splenic cDCs from RAG-/- mice to present soluble antigen was 
already shown before (143), although the authors worked with skin-derived DCs and 
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tested their antigen presenting ability in different experimental system. In this work, 
the authors showed that reconstitution of RAG deficient mice with T cells could 
rescue the function of DCs. Thus, they hypothesized that DCs need T cells for 
functional maturation in vivo (143). 
In my work, I could extend the functional deficiency described above to cDCs found 
in the spleen of RAG deficient mice. I decided to go deeper into the molecular details 
and possibly find independent mechanistic explanations for the impaired function of 
such DCs.  
First, the expression of various surface molecules did not reveal any significant 
differences between RAG-/- and WT cDCs, except that reproducibly I could detect 
higher levels of MHC I and MHC II molecules on cDCs from RAG deficient mice in 
comparison to WT cDCs. A first possibility, namely that RAG-/-cDCs were more 
mature than WT cDCs, could be excluded on the basis of comparable phagocytic 
activity and similar levels of co-stimulatory molecules. In addition, cDCs that would 
have matured due to inflammatory stimuli would up-regulate the expression of MHC I 
and MHC II molecules to a much greater extend than found here. Finally, the analysis 
of the transcriptional profile did not reveal a significant difference in maturation 
between WT and RAG-/- splenic cDCs. 
However, from the transcriptional profiling of both types of cDCs new insights into 
the nature of the RAG-/- cDCs deficiency could be gained. Three groups of genes were 
differentially expressed in splenic cDCs in the absence of T and B cells.  
One group of genes was encoding endo-lysosmal enzymes, which are responsible for 
degradation of antigen. Their up-regulation in RAG-/- cDCs strongly suggested a more 
aggressive degradation than in WT cDCs. Indeed, this hypothesis was confirmed 
experimentally by flow cytometry employing DQ-OVA or imunoblot with 
biotinylated OVA. Consistent with this idea, efficient cross-priming of CD8+ T cells 
was shown to require the presence of antigen storage compartments in DCs (93). Such 
compartments were described as lysosomal-like organelles. Therefore highly 
aggressive degradation of antigen in RAG-/- cDCs would lead to a reduction of this 
intracellular antigen depot, and thus a reduction in cross-priming efficiency. 
In the second group of genes C1q complement family members were found. Beyond 
their very well established role in activation of the classical complement pathway, C1q 
components are also responsible for clearance of apoptotic debris (155). Therefore, it 
was possible that RAG-/- cDCs are specialized to presentat of particular antigens, like 
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cell-associated antigens derived from apoptotic cells. Indeed, presentation of antigen 
associated with apoptotic bodies was equally efficient by cDCs from both types of 
mice. 
Interestingly, when I tested the spleen of RAG deficient mice for the number of 
apoptotic cells, I could detect much more of them than in WT spleen. Thus, the lack of 
particular cells in the spleen of RAG deficient mice lead to an increase in the numbers 
of apoptotic cells, possibly due to a lack of survival signals derived from T or B cells. 
This might explain, why the percentage of cDCs in the spleen of such mice is similar 
to WT mice. The total number of cDCs needs to be dramatically reduced since the 
cellularity of RAG-/- spleen is also strongly reduced. As a consequence, RAG-/- cDCs 
may favor to phagocytose dead cells and present cell associated antigens. 
The third group of genes concerned cell surface receptors responsible for up-take of 
soluble antigen (like the mannose receptor) as well as Fc receptors for 
immunoglobulins. Indeed, the ability of RAG-/- mice to acquire soluble OVA, was 
slightly enhanced in comparison to WT cDCs. On the other hand, high expression of 
Fc receptors could indicate that signaling via these receptors might be important for 
the functional fine-tuning of splenic cDCs. Engagement of FcγRIIB on DCs was 
shown to enhance their maturation as well as their ability to present antigen via both 
MHC I and MHC II (147, 148).  
Fc receptors are normally expressed as receptor pairs - activating together with 
inhibiting - and in steady state there is maintenance of a strict balance between those 
two forces. Thus, disturbances of this homeostatsis may lead to improper 
activation/inhibition of cellular functions. The absence of B cells or immunoglobulins 
produced by them, might therefore explain the distorted function of splenic cDCs from 
RAG-/- mice. 
Indeed, reconstitution of RAG-/- mice with WT B cells rescued the impaired ability of 
splenic cDCs to cross-present soluble OVA. Moreover when purified 
immunoglobulins were administered, the same effect could be observed. The latter 
finding excluded the possibility that the rescue of cDCs function by B cells was due to 
production of cytokines or other mediators by such cells.  
Therefore, the most likely explanation of the impaired APC function of cDCs from 
RAG-/- mice is the absence of immunoglubilins in the circulation. The binding of 
immunoglobulins to the FC receptors in WT mice could either positively drive the 
cDCs into a maturation state, that allows efficient presentation of soluble antigens. 
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However, I think it is more likely that such immunoglobulins exert an inhibitory 
signal, e.g. by binding to FcγRII that tames the aggressive degradation mechanisms in 
WT cDCs. This hypothesis is testable. It would predict that splenic cDCs from 
recombinant mice that lack the required activating or inhibitory Fc receptors will show 
the same phenotype as splenic cDCs from RAG-/- mice.  
An aspect that has been ignored so far is the concurrent influence of T cells that has 
been shown for skin-derived DCs (143). For the time being, it cannot be excluded that 
reconstitution of RAG-/- mice with T cells would similarly recover impaired cross-
presentation by RAG-/- splenic cDCs. Such experiments are crucial for a complete 
picture. Possibly, the presence of both, B and T cells is essential for maintenance of 
proper function of splenic cDCs. Yet, this still remains to be elucidated. 
Together, I could demonstrate that the absence of T and B lymphocytes changes the 
character and function of cDCs in the spleen. The deviant character of cDCs from 
RAG deficient mice could exemplify the adaptation to particular cellular composition 
and particular molecules present in the spleen. Therefore, one should be aware of such 
limitations when using of RAG-/- mice for experiments of T cell regulation, tolerance 
induction and APC - T cell interaction in general. On the other hand it represents the 
most beautiful example of the complex homeostatic interaction and dependency of the 
innate and adaptive immune system. 
 
6.3 MZ B cells efficiently stimulate NKT cells proliferation and production of IL-4 
 
Expression of the MHC I b molecule CD1d by MZ B cells had already been described 
before (64, 150-152, 164, 165). The exceedingly high expression of CD1d was 
revealed by the direct comparison of various cell types in the present work. Since 
CD1d is the restricting molecule for NKT cells, the capacity of MZ B cells to 
stimulate NKT cells was tested. Interestingly, MZ B cell sensitized with αGalCer were 
very efficient in priming NKT cells in vitro. In fact, they were better than cDCs that 
also expressed considerable amounts of CD1d. The two other splenic B cell 
populations - B1 and B2 cells - completely failed to activate NKT cells although they 
expressed CD1d to some extend.  
A recent study (151) showed that MZ B cells require DCs to activate NKT cells, 
although this work had some flaws since the purity of NKT cells employed was only 
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around 50%. However, this raises the question whether my results are also due to DCs 
present in the cell preparations. I think, I can rule out this possibility. NKT cells were 
sorted to purity greater than 98% as were the APCs. In addition, one would expect that 
the other B cell populations would also have triggered NKT cells under these 
conditions. This was clearly not the case. Moreover, in this work the authors did not 
observe TH1/TH2 dichotomy when different APCs were used for NKT cells 
stimulation. Since in my case this is a very robust result, the controversy is most likely 
due to undefined cell populations in the particular assays employed.  
In my hands, co-culture of αGalCer sensitized cDCs with NKT cells reproducibly 
induced the production of IFN-γ in many of the responder cells while IL-4 producing 
cells were scarce under these conditions. In contrast, MZ B cells induced mainly IL-4, 
especially early after stimulation. In addition, MZ B cells failed to induce secretion of 
IFN-γ by NKT cells. The capacity to induce proliferation of NKT cells was 
comparable for both, cDCs and MZ B cells. The differentiation of NKT cells was 
drastically influenced by the type APC employed. MZ B cells directed the response 
into a direction that should favor TH2 response while cDCs induced TH1 like 
conditions. 
In similar published studies, bulk sorted B cells were employed to test their 
stimulatory capacity for NKT cells (164). Such B cells alone were able to activate 
NKT cells. However, stimulatory capacity was 2- to 3- fold lower than that of cDCs. 
Interestingly, the authors observed a dichotomy of TH1 and TH2 differentiation 
dependent of whether the NKT cells were stimulated by DCs or B cells. Similarly 
Kitamura et al.(166) showed that αGalCer induces early B-cell activation through 
production of IL-4 by NKT cells. Again the authors tested a bulk B220+ B cell 
population only. 
Such findings were also reminiscent of the work by Stockinger et al. (167). They could 
observe a difference in the cytokine pattern elicited in CD4+ T cells dependent of 
whether they used DCs or B cells as APC.  
All such findings lack a confirmation of relevance in vivo. In contrast, I provide an in 
vivo confirmation of my findings. Injection of sensitized cDCs or MZ B cells into 
CD1d deficient mice that had been reconstituted with NKT cells or into WT mice 
(data not shown) revealed that the dichotomy observed in vitro was even more 
pronounced in vivo. MZ B cells exclusively stimulated NKT cells to differentiate into 
IL-4 producers, while cDCs almost exclusively induced IFN- production in NKT 
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cells. This indicates that the reaction I have observed here might have important 
implications for the initiation and regulation of defensive immune responses in vivo. 
The direction of the NKT cells response clearly depended on the type of APC that was 
presenting an identical antigen via the same CD1d molecule. Hence, I hypothesized 
that such APCs should be distinct in the co-stimulatory molecules that are engaging 
the NKT cells. Thus, several surface receptors and ligands on APCs as well as on 
NKT cells were examined. Interestingly, differential expression of two ligands, 
GITRL and ICOSL, on MZ B cells in comparison to cDCs was observed. Both of 
them were significantly higher expressed on MZ B cells. 
The role of GITR in NKT cells activation is still controversial. Some studies showed 
that engagement of GITR leads to co-stimulation of NKT cells and increases 
production of IFN-γ and IL-4 (156). In contrast, others demonstrate that GITR 
engagement elicits co-inhibitory activity for antigen-induced NKT cells (168). This 
controversy appears not to be entirely resolved yet.  
In my study, blockage of GITR by antibodies did not alter the ability of NKT cells to 
proliferate in response to both, MZ B cells and cDCs. However, IFN-γ production 
after stimulation of NKT cells by cDCs was significantly inhibited while the response 
of IL-4 elicited by MZ B cells was not influenced. Therefore, the GITR/GITRL 
pathway appears to be dispensable during MZ B cells induced NKT cells 
differentiation. In contrast, for differentiation of NKT cells into TH1 supporting cells 
this interaction appears to be essential.  
ICOS/ICOSL interaction was shown to have a major role in the expansion of TH2 
immune responses (155, 157). In vivo blockade of ICOS affects TH2 effector functions 
(157, 169). Presence of a functional ICOS/ICOSL pathway was shown to be crucial 
for the development of allergic airway disease and to development of allergen specific 
TH2 cells (155, 157). ICOS is known to be highly expressed on T cells after their 
initial activation (170), therefore ICOS/ICOSL interaction might be most influential 
early during MZ B cells and NKT cells interactions. Moreover characterization of 
ICOS-/- mice revealed that T cells isolated from these animals are not able to produce 
IL-4 (171).  
Importantly, I showed that inhibition of ICOSL on MZ B cells leads to complete 
abrogation of NKT cells proliferation and IL-4 production. This experiment strongly 
suggested that MZ B cells via ICOS/ICOSL interaction drive NKT cells proliferation 
and early IL-4 production that might be decisive for elicitation a TH2 type of response. 
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The scenario that starts to appear based on the present results is as follows: MZ B cells 
act as professional antigen presenting cells of the marginal zone. Moreover, the MZ B 
cells play a special role with regards to regulation of immune responses. NKT cell 
stimulated by MZ B cells might induce a cytokine milieu that drives naive CD4+ T 
helper cells to differentiate into TH2 cells. Presence of functional ICOS/ICOSL 
pathway is necessary for both NKT cells expansion as well as production of IL-4 by 
NKT cells. 
Thus, lipids of particular blood borne pathogens that have a high preference to interact 
with MZ B cells will lead to a TH2 inducing milieu by the NKT cells. In contrast, 
lipids of most blood borne pathogens will interact with cDCs in the marginal zone and 
thus induce a TH1 milieu. In consequence, strong triggering of NKT towards one or 
the other direction by either MZ B cells or cDCs will have a strong influence on the 
subsequent immune reaction. Hence, this interaction should be decisive of whether the 
response will be protective or detrimental. 
 
6.4 Concluding remarks 
 
My work reflected on the importance of APCs for the immune system. First, I could 
demonstrate the importance of IFN-β for the development of cDCs via up-regulation 
of Hsp70.1 and Hsp70.3 under steady state conditions. The identification of such heat 
shock proteins as interferon regulated genes had been missed thus far. Up-regulation is 
only observed when low amounts of IFN-β are applied as they are found under steady 
state. Amounts of IFN-βthat are encountered under inflammatory conditions, led to a 
negative feedback regulation of Hsp70.1/3.  
Second, immunoglobulins appear to be important regulatory molecules for the 
maturation of cDCs. Antibodies were clearly believed to be involved in antigen 
presentation because antibody/antigen complexes might be preferentially endocytosed 
via Fc receptors and engagement of these receptors might provide activating signals. A 
direct regulatory function of not complexed immunoglobulins on the differentiation of 
cDCs is novel and unexpected.  
Finally, I could provide suggestive evidence that MZ B cells are involved in the 
decision for the TH1/TH2 bias. I could show that such B cells trigger NKT cells to 
proliferate and to differentiate into IL-4 producers. Since NKT cells are known that 
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they respond extremely rapidly upon antigen stimulation, this interaction might be a 
key reaction for the regulation of protective immune responses. 
Thus, I believe that my thesis is an important corner stone in the understanding of the 
complex regulatory mechanisms shaping the immune system and its reactions. 
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SUMMARY 
Antigen presenting cells (APCs) represent one of the most important cell types of the 
immune system. They are crucial for the initiation of a protective adaptive immune 
responses as well as for maintenance of tolerogenic conditions and tissue homeostasis. 
Therefore, how the function of APCs is regulated represents an extremely important 
aspect in understanding the decisions made during an immune response. The work I 
presented here, addressed the questions how single molecules, cellular composition of 
the spleen and particular anatomical location influence the character and outcome of 
an immune response. It was of particular interest how the function of splenic APCs 
can be established in steady state conditions. 
Taken together the results presented here show that: 
 IFN-β and type I IFNs signaling are essential factors for proper antigen presentation by 
splenic cDCs in steady state; 
 Absence of IFN-β can be recovered by already very low amounts of exogenous IFN-β. 
This is reminiscent of low amounts of IFN-β constitutively produced under steady 
state conditions; 
 Lack of IFN-β or type I IFNs signaling leads to down-regulation of members of Hsp70 
family in splenic cDCs, which serve as molecular chaperones during antigen 
presentation via both MHC I and MHC II; 
 The antigen presenting ability of Hsp70.1/3-/- cDCs revealed the same phenotype as 
IFN-β-/- and IFNAR-/-cDCs. This confirmed that constitutive levels of type I IFNs by 
regulating the Hsp70 levels, ensures that antigen presentation in steady state works 
properly and efficiently; 
 These data suggest that constitutively produced low amounts of type I IFNs are 
important not only for presentation of pathogen derived antigens, which do not induce 
robust IFNs response, but also for presentation of self antigens in steady state, which 
might be crucial for maintenance of tolerance and tissue homeostasis; 
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 Absence of T and B cells has important implications on character and function of 
splenic cDCs. They are impaired in their presentation capacity for soluble antigen; 
 cDCs from RAG-/- mice exhibit a more aggressive antigen degradation pathway than 
cDCs from WT mice; 
 Reconstitution of RAG-/- mice with soluble immunoglobulins is sufficient to recover 
impaired function of cDCs to present soluble antigen; 
 Particular anatomical location and high expression of CD1d on the surface of MZ B 
cells enable them to be very efficient activators of NKT cells in vitro and in vivo; 
 Compared to cDCs, stimulation of NKT cells by MZ B cells lead to exclusive 
production of IL-4; 
 To stimulate NKT cell proliferation and IL-4 production MZ B cells utilize the 
ICOS/ICOSL co-stimulation pathway; 
 Different anatomical location and access to antigen seems to be decisive for the nature 
of induced immune response, cDCs rather favor TH1 conditions, whereas MZ B cells 
TH2; 
 
These results shed a new light on how the antigen presentation by splenic cDCs is 
regulated in homeostatic conditions. Importantly, they revealed the sensitivity of this 
process on a single soluble molecule, i.e. IFN-β. Studying and characterizing of cDCs 
from RAG-/- mice revealed an unexpected critical role of B cells and immunoglobulins 
and their influence on the function of cDCs. Furthermore, results presented here may 
contribute to a deeper understanding of the initiation of the TH1 versus TH2 bias. This 
is decisive for the type of induced immune response, TH1 favor cell mediated 
immunity and TH2 will promote humoral responses. Thus, my work underscores the 
complexity of the cellular and molecular requirements for the development of a 
functional immune system. But I was also able to provide new mechanistic insights 
into such regulatory mechanisms. 
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FREQUENTLY USED ABBREVIATIONS 
 
APCs – antigen presenting cells 
 
Ag – antigen 
 
Ab – antibody 
 
APC – allophycocyanin 
 
αGalCer – α- galactosylceramide 
 
BCR – B cell receptor 
 
BM – bone marrow 
 
β2m – β2 microglobulin 
 
CFSE – carboxyfluorescein succinimidyl ester  
 
Cy – cyan 
 
cDCs – conventional dendritic cells 
 
DCs – dendritic cells 
 
DSG – 15-deoxyspergualin 
 
e.g. – for example 
 
EDTA –  ethylenediaminetetraacetic acid 
 
ELISA –  enzyme-linked immunosorbent assay 
 
ER – endoplasmic reticulum 
 
FACS – fluorescence activated cell sorter 
 
FcγR – Fcγ receptor 
 
FCS – fetal calf serum 
 
Fig. – figure 
 
FITC – fluorescein isothiocyanate 
 
FSC – forward scatter characteristics 
 
hi – high 
 
Hsp – heat shock protein 
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HZI – Helmholtz Zentrum für Infektionsforschung (Helmholtz Centre for Infection Research) 
in Braunschweig, Germany 
 
i.e. – this is 
 
IFNs – type I Interferons 
 
Ig – immunoglobulin 
 
IL – interleukin 
 
IMDM – Iscove's modified Dulbecco's medium 
 
int –  intermediate 
 
i.v. –  intravenously 
 
KO –  knockout 
 
LN – lymph node 
 
lo – low 
 
LPS – lipopolysaccharide 
 
MFI – mean fluorescence intensity 
 
Mφ – macrophage 
 
MHC – major histocompatibility complex 
 
MIIC – MHC class II compartment 
 
MZ – marginal zone 
 
MZ B cells – marginal zone B cells 
 
NKT cells – natural killer T cells 
 
OD – optical density 
 
ONPG – ortho-nitrophenyl-β-galactoside 
 
OVA – ovalbumin 
 
OVA-bio – biotynylated ovalbumin 
 
pDCs – plasmacytoid dendritic cells 
 
PAMPs – pathogen associated molecular patterns 
 
PBS – phosphate buffered saline 
 
PCR – polymerase chain reacition 
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PE – phycoerythrin 
 
PI – propidium iodide 
 
PMA – phorbol myristate acetate 
 
PMSF – phenylmethylsulphonyl fluoride 
 
Poly(I:C) – polyinosinic:polycytidylic acid 
 
PVDF –  polyvinylidene difluoride 
 
qRT-PCR – quantitative real-time PCR 
 
PRR – pathogen recognition receptors 
 
RIPA – radio immuno precipitation assay 
 
RAG – recombination acitvated gene 
 
RT – room temperature 
 
SSC – side scatter characteristics 
 
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
TAP –  transporter associated with antigen processing 
 
TCR – T cell receptor 
 
TLR –  toll-like receptor 
 
TH – T helper cell 
 
tg –  transgenic 
 
UV –  ultraviolet 
 
WT – wild type
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